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1.0 INTRODUCTION
1.1 Abstract
Since its introduction in 2006, the human papilloma virus (HPV) vaccine has made
substantial developments. The use of the vaccine was expanded to include males. The
completion dose series was decreased from three to two shots, if started before the age of
15. The cost of the vaccine is fully covered by private insurance and public programs for
various ages ranging from 9 to 26 years old1. With these improvements the HPV vaccine
has the capability to safely and significantly prevent and reduce many cancers that cause
the deaths of women and men across the United 1,2. Therefore, the underuse of the HPV
vaccine is a serious but correctable threat to progress against cancer3,4. During 20122016, an estimated average of 34,800 HPV-attributable cancers were diagnosed each
year. Among these estimated cancers, 92% were attributable to the HPV types that are
included in the 9-valent HPV vaccine and could have been prevented if HPV vaccine
recommendations were followed5. However, HPV vaccination rates across the U.S.
remain low6.
Using public health data sources, choropleth maps, new variables of Health Department
(HD) clinic access and prediction modeling, this research advanced the field of health
services research by informing the third goal of the President’s Cancer Panel 2012-2013
report: maximize access to HPV vaccination3. The short-term impact of this research
quantified and located HPV vaccination for adolescents, in addition to highlighting
prognostic indicators of access and identifying barriers to HPV vaccination uptake among
HD clinics at the county level in Georgia. The long-term impact of this research provided
greater insight for targeting efforts to optimize HPV vaccine uptake at the county level in
4

South Carolina and in other states with low HPV vaccination coverage. This research
demonstrated the important use of small area estimation by public health professionals in
states with low HPV vaccination coverage and limited or no immunization registry data
for small geographic areas. This research provided valuable data toward the access of
vaccination services and the dissemination and implementation of HPV vaccination
interventions at the county level. Ultimately the findings from this study may be used to
predict correlations to the incidence of HPV-associated cancers, which may help reduce
public health costs, morbidity and mortality related to HPV infections in the United
States.
1.2 Specific Aims
The underusage of the human papilloma virus (HPV) vaccine is a serious but
correctable threat to the prevention of cancer4. More than 90% of cervical and anal
cancers, approximately 70% of vaginal and vulvar cancers, 60% of penile cancers, and
about 70% of oropharyngeal cancers are a result of a HPV infection7. As of 2019, 54.2%
of U.S. adolescents are fully vaccinated with the HPV vaccine, and 71.5% of them have
received at least one dose of the HPV vaccine average6. National efforts to increase HPV
vaccination to 80% are being made8 and include resources often administered and utilized
at the county level through the state health department (HD). However, the lack of county
level HPV vaccination coverage data in many states is a major obstacle to effectively
monitor health department resource utilization. Efficiently allocating health department
resources is necessary to improve HPV vaccination coverage and ultimately protect
adolescent residents from HPV-attributable cancers9,10.
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The overarching goal of this research is to generate a predictive model of county
level HPV vaccination coverage rates in SC and Georgia (GA) to address access barriers
to HPV vaccine uptake. Because the tetanus, diphtheria and pertussis (Tdap) vaccine is a
school mandated vaccine for all adolescents in both states and an indicator of access to
vaccination services, we evaluated adolescents who received the HPV vaccine among
those who have received the Tdap vaccine. Using factors associated with HPV
vaccination we will evaluate additional indicators of access to health department (HD)
clinics: the number of public and private clinics, the number of HD clinics with Vaccine
For Children (VFC) provider registration, and availability of public transportation. We
used the number of administered HPV and Tdap vaccine doses previously collected from
each state’s immunization registry for the years 2016-2018. Given that SC and GA are in
the same Region 4 of the Department of Health and Human Services (HHS) and their
population demographics are similar, it is expected that vaccination rates in SC’s counties
would be comparable to GA’s counties. However, GA’s adolescent HPV vaccination
coverage trend of greater than or equal to one dose exceeds or is close to the national
average. When population subgroups share characteristics, the systematic underuse of
vaccination services may indicate a problem with the equity of access11. Eliciting a
secondary data analysis of the vaccination data from both states, we evaluated our
primary hypothesis that HPV coverage rates are associated with the equity of access to
health department clinics. To test this hypothesis the following specific aims were
completed:
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1.2.1 Aim 1
Specific Aim 1: Characterize all counties in GA based on administered doses
of the HPV vaccine, the Tdap vaccine and HD clinic access. Graphical maps were
created for each state using Bayesian spatial analysis of HPV and Tdap vaccine doses,
public transportation routes and VFC provider registration by public and private health
clinics. Hypothesis 1.1: In GA, administered doses of the HPV vaccine and the Tdap
vaccine will be associated with indicators of HD clinic access.
1.2.2 Aim 2
Specific Aim 2: Develop and validate a predictive model to describe the
association between county level HPV vaccination coverage and HD clinic access in
GA among Tdap vaccinated adolescents. Controlling for known factors associated with
HPV vaccination, we used 2016 and 2017 data from GA to predict 2018 HPV
vaccination coverage rates. Hypothesis 2.1: Significant factors of HPV vaccination
coverage will be predicted at the county level in GA among Tdap vaccinated adolescents.
1.2.3 Aim 3
Specific Aim 3: Apply the predictive model of HPV vaccination coverage
developed from GA data to SC. Using the final model selected in Aim 2, the best set of
beta estimates were applied to all counties in SC via linear regression to predict HPV
vaccination coverage. Hypothesis 3.1: Differences in SC’s HPV vaccination coverage
between observed and predicted rates will be identified.
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2.0 BACKGROUND
2.1 Overview
This dissertation research builds upon and extends my mentor’s current research of a
statewide HPV vaccination awareness campaign in South Carolina to increase HPV
vaccination rates. Using the adolescent population (ages 13-17) of South Carolina, two
primary research questions are examined: 1) who is getting vaccinated and 2) what can be
done to improve HPV vaccination. These research questions prompted the consideration
of a better tool for HPV vaccination surveillance.
2.2 Introduction
In 2016, South Carolina had the lowest rate of HPV vaccine completion among
adolescent girls in the United States (30.8%) and second-to-last for up-to-date (UTD)
vaccination among adolescent boys (27.4%). In 2017, 38% of males and 47.4% of
females were up-to-date12. As a result, South Carolina had the third largest increase in
HPV vaccinations in the United States from 2016 to 2017. Currently, South Carolina is
close to the national average of 54.2%6 but the Healthy People 2030 goal is to reach
80%8. Problems with access to care as they relate to HPV vaccination in South Carolina
consist of barriers at different levels within the patient, provider, health system and
political environment. Patient barriers include: lack of provider recommendation, lack of
knowledge about the vaccine and HPV related diseases, concerns about vaccinating an
adolescent against a sexually transmitted infection, the disbelief that the vaccine is
essential, particularly with males, and concerns about the vaccine’s safety and cost.
Provider barriers include: a lack of understanding about HPV-related diseases,
specifically for males, safety concerns about the vaccine, concerns about reimbursement
8

for vaccines, personal attitudes, being uncomfortable with talking to parents and children
about a topic related to sexual behavior, concerns about parental resistance, preferring to
vaccinate older rather than younger adolescents, lack of vaccine reminder and recall
systems, and limited time to provide education about the vaccine. Health system and
political barriers include: the lack of electronic health record reminders13, a lack of
vaccine insurance coverage among some populations and a lack of legislation for
mandatory vaccination 14.
However, South Carolina is just a small piece of the big picture, as national and
state levels HPV vaccination coverage rates still vary by geography and race. Reported
disparities by geographic location broadly reference metropolitan vs non-metropolitan
areas. HPV vaccination rates are particularly low in rural areas even though the uptake of
other adolescent vaccines is comparatively higher. In urban areas over 50% of the
adolescents are up to date on their HPV vaccination compared to 42% of adolescents in
rural areas15. Racial disparities have been reported among Black, Hispanic and Asian
adolescents being more likely to initiate the HPV vaccine series compared to White
adolescents, but less likely to complete the vaccine series16. Previous studies have also
identified factors at the local level associated with HPV vaccination coverage are the
uptake of other adolescent vaccines, gender, race/ethnicity, socioeconomic status,
religiosity, political ideology, education policies and insurance status17–19. Religiosity and
political ideology have been used as proxy measures for macro-level acceptability and
attitude towards the HPV vaccine19. Differences in HPV vaccination uptake also exist
between certain geographically distinct populations and among adolescents who have
received the school mandated tetanus, diphtheria and pertussis (Tdap) vaccine. While
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mandates have been effective with other vaccines, states with HPV vaccine mandates
have similar rates of HPV vaccination compared to those without mandates, thus
indicating that differences are not fully understood 18,20. While there is a need to further
explore these disparities, within state variability of HPV vaccination is either unknown or
rarely reported21 and in some states county level HPV vaccination coverage rates are
currently not available.
In terms of barriers, a distinct contributing factor to incomplete HPV vaccination
among adolescents is parental hesitancy. Parental hesitancy contributes to missed
opportunities22, physician hesitancy 3, and the physicians’ perception of parental
reservations 23. In 2014 a qualitative study was published that investigated the rationale of
parents/guardians and providers for delaying or administering the HPV vaccination to
girls. Among providers who reported that over 80% of their patients receive HPV
vaccination, the higher uptake was driven by always recommending co-administration of
HPV, tetanus, and meningococcal vaccines and emphasizing cancer prevention22. Many
of the missed opportunities for HPV vaccination were due to parents and providers
agreeing to delay vaccination until the risk for sexual activity was predicted22. Other
studies have reported that health care providers also perceived parental attitudes and
hesitancy related to vaccinating an adolescent against a sexually transmitted infection as a
barrier. Lack of provider recommendation, in turn, is one of the most influential reasons
why parents do not get their adolescents vaccinated against HPV. Additional key
contributors of parental hesitancy are needing more information about the HPV vaccine,
the belief that their child is too young for the vaccination, safety of the vaccine, cost of
the vaccine, and finding a clinic that offers the HPV vaccine 23.
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To address parental hesitancy effective HPV vaccine messaging in an important
strategy to increase HPV vaccine uptake. In South Carolina, the most trusted messengers
include healthcare organizations, and providers, patient and parent peers, and local public
figures24–26. Messages that appeal to parents’ moral responsibility to protect children
against cancer are recommended due to moral values such as purity and liberty being
associated with vaccine hesitancy. Additionally, messages that highlight HPV’s
connection to sexual activity negatively influenced vaccine-hesitant parents, specifically
in South Carolina due to a large population that identifies as Christian. Therefore,
disseminating messages from the CDC that highlight cancer prevention, knowledge about
HPV transmission, risks and prevention are recommended. Examples of messages are
“The HPV vaccine is safe, effective and provides long-lasting protection”, “HPV Vaccine
is Cancer Prevention” and “One vaccine plus two doses equals protection against six
types of cancer”. Overall, HPV-specific messages that align with constructs from
behavior models such as the Health Belief Model and Social Cognitive Theory to
communicate the high risk for HPV infection, the severity of cancers associated with
HPV, a cue to action for parents to protect children from known risk and the
normalization of HPV vaccination as standard practice are effective 26. Recommended
strategies for disseminating these messages are using personal stories from cancer
survivors and parents who have vaccinated their children. Additionally the use of trusted
experts to discuss scientific data emphasizing the safety and efficacy of the HPV vaccine
across multiple media platforms will engage a wider audience and effectively
communicate the benefits of the vaccine to parents26.
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2.3 Molecular Biology of HPV that Drives Carcinogenesis
Papillomaviruses are a distinct taxonomic family, the Papillomavirida. The bovine
papillomavirus type 1 (BPV-1) and human papillomavirus type 1a (HPV-a1) genomes
were the first papillomavirus genomes to be completely sequenced. Interestingly, the
BPV-1 has been utilized as a prototype for studies of the molecular biology of
papillomaviruses. Papillomaviruses replicate and assemble entirely in the nucleus of a
cells. The expected replication cycle has an early and a late phase. The early phase
includes viral entry, and the initial viral genome replication, stimulation of cell division
and inhibition of apoptosis in the infected cell. The late phase includes viral genome
amplification, virion formation and its release into the surrounding environment from the
surface of the epithelium. Specifically during the early phase the virus infects the
keratinocytes (basal cells) in the basal epithelial layers 27,28. Once infected, basal
epithelial cells divide, the viral genome copies are replicated and separated equally into
daughter cells. An infected daughter cell will make multiple copies and move up through
the various epithelial layers. During this process there is a pattern of viral gene
expression in response to epithelial differentiation that is specifically connected to
different epithelial layers 27.
The viral genome responds by expressing viral regulatory proteins: E1, E2, E4,
E5, E6 and E7 from the early region of the viral genome and two structural viral capsid
proteins: L1 and L2 from the late region of the genome28. E1 and E2 support viral DNA
replication and the regulation of transcription so that the infected basal cells can be
maintained for a long period. E4 is linked with reassembling differentiated basal cells for
the release of progeny viral particles and regulation of the cell cycle. E5, E6 and E7 are

12

viral oncogenes and their expression initiates cell immortalization and transformation by
coordinating a host cell environment suitable for viral DNA replication which promotes
host cellular DNA synthesis and prevents apoptosis. E5 is involved in keratinocyte
signaling and immune evasion. E6 and E7 inactivate interferon (IFN) regulatory factor
(IRF) so that the viruses can remain as persistent, asymptomatic infections in
differentiating epithelial cells where cell division would normally be repressed. L1 and
L2 are expressed in cells replicating viral DNA in the upper epithelial cells. Taxonomic
status of papillomavirus types, subtypes, and variants is based on the sequence of their L1
genes which differ from each other by at least between 2 – 10% 27–29.
Papillomavirus infections typically result in benign lesion however, the human
papillomavirus (HPV) infection sometimes develops cancerous lesions. HPV is a small
non-enveloped deoxyribonucleic acid (DNA) virus that infects skin or mucosal cells. The
circular, double-stranded viral genome of about 8 kilobases in length. As a member of
Papillomavirida, the HPV genome encodes for 6 early proteins responsible for virus
replication and 2 late proteins that are the viral structural proteins. The cancerous lesions
emerge once HPV infects a cell and produces oncoproteins E6 and E7 that are
particularly instrumental in the conversion of normal cells to cancerous ones. These
inappropriately dividing cells in the upper epithelial layers would normally be disposed
via apoptosis but E6 promotes tumor cell growth by breaking down the tumor suppressor
protein p53 and inactivating pro-apoptotic proteins such as Bak or Bax. E6 degrades p53
thorough the ubiquitin pathway by targeting it for proteasome mediated degradation
which allows HPV infected cells to survive and support replication 27,30. Normally, the
tumor suppressor protein p53 prevents the transition of cells from the checkpoint G1

13

phase to the replication S phase, thus allowing for the repair of damaged DNA or the
initiation of apoptosis.
For that reason it has been suggested that high risk HPV types do not have a
functional G1 checkpoint and that the E6 protein has been shown to influence the
telomerase enzyme to elongate chromosomal telomeres which is necessary for cell
immortalization 31. As a result, the ability to target p53 for degradation contributes to the
impact of oncogenic activity. With high risk HPV type E6 proteins, the interaction of an
E6-associated protein (E6-AP) is necessary for the complex formation of E6 with p53.
Furthermore, the E6-AP can initiate the ubiquitination of cellular components without
E6, so the function of E6-AP is not just to mediate the binding of E6 to p53, but it
provides the functional link to the ubiquitin system as an E3 ubiquitin ligase. However,
this complex formation is not definitively seen with low risk HPV type E6 proteins 32.
The weak interaction between low risk HPV type E6 proteins may explain their inability
to target p53 for degradation, resulting in a lack of oncogenic activity. However, it is also
possible that additional proteins are required to facilitate the interaction of E6-AP with
low risk HPV type E6 proteins and/or that the E6-AP complexes are not detectable under
current conditions of coprecipitation experiments 33. The E6 protein further cooperates
with the E7 protein to convert normal cells to cancerous one. E7 binds to the
retinoblastoma protein (pRb) in the pocket domain. The pocket domain sequences are
necessary for its tumor suppressor function which negatively regulates the cell cycle in
the G1/S and G2/M transitions.
In a normal cell, pRb and E2F- family transcription factors regulate cell
replication together by keeping the cell ‘off’ in the resting phase, G0, before the cell goes
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into mitosis and divides. Therefore when E7 blocks the interaction between pRb and
E2F-family transcription factors, it activates the E2F factors to stimulate replication and
cell division 27,30. Specifically, when bound to pRB, E7 promotes C-terminal cleavage of
pRB by the calcium activated cysteine protease calpain which is required for the
proteasomal degradation of pRb. Additionally, E7 may initiate cancerous cell
transformation by binding the AP1 transcription factors to prevent the differentiation of
keratinocytes and by interfering with other cell cycle regulators such as cyclin A and
cyclin-dependent kinase2 29,31. However, E7 proteins from low risk HPV types inactivate
cellular pRB tumor suppressor proteins less efficiently than high risk HPV types 28 and
the genetic variation of E7 within an HPV type in specific regions of the viral genome
has been suggested to impact carcinogenicity. Specifically, in a recent study with cervical
cancer it was shown that the conservation of the 98 amino acids of E7 is critical for HPV
16 carcinogenesis. Even compared to E6, E7 has significantly fewer, rare non-silent
genetic variants in cancers and E7 was shown to be less constrained in benign infections.
These results were consistent in different geographic locations and racial groups and thus
suggests that E7 genetic variation notably decreases the risk of invasive cancer 34.
HPV is the most common sexually transmitted infection in the United States but
only approximately 10% to 15% of infected persons have persistent infections, of which a
small portion has the potential to progress to invasive cancer 35. This suggests that host
defense mechanisms are successful at clearing the initial HPV infection for the majority
of HPV infected persons. Host defense mechanisms against HPV are physical barriers,
innate immunity and adaptive immunity. Physical barriers of basal keratinocytes, the host
cells of HPV, are the skin and mucous membranes secrete a thick protective fluid and
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antimicrobial peptides. HPV moves across the skin and mucous membrane via tissue
damage and once inside many of its particles are degraded via host autophagy. The
nuclear envelope also blocks HPV DNA from entering the nucleus. Innate immunity uses
pathogen sensors to recognize HPV DNA once HPV enters a host cell. The high
expression of nucleic acid-sensing toll-like receptors (TLR) is significantly correlated to
women clearing the initial HPV infection. The HPV infected microenvironment also
attracts dendritic cells, Langerhans cells, natural killer cells and natural killer T cells, thus
suggesting that the early inflammatory response may be critical for initiating a strong
defense against HPV infection. Adaptive immunity is seemingly less instrumental
because the HPV lifecycle is only intraepithelial, and virions are only produced from the
fully differentiated upper layer of skin. In the outer layers of epithelium, viral DNA is in
capsids and progeny virions are released to re-initiate infection. Therefore, there are no
virus induced cell eruptions or released viruses in the blood. However, host T cell
responses are required to eliminate HPV infected cells. To escape being detected by the
immune system HPV alters host gene expression, dysregulates protein functions, hides
surface expression of MHC-I molecules to evade immune defenses and establish
persistence. As a result, the continued presence of the viral genome over a period of
several years in actively dividing epithelial cells results in a persistent infection 27,29,35.
2.4 Etiology of HPV Vaccine Development
While 90% of HPV infections do not show symptoms and clear naturally within
two years, persistent infections can cause cancer and genital warts. There are more than
100 types of HPV. More than 40 HPV types can infect the genital areas of men and
women, including the skin of the penis, vulva, and anus, as well as the linings of the
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vagina, cervix, and rectum. These types can also infect the lining of the mouth and throat.
Of these, 13 HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 66) can cause
cervical cancer, and one of these types can cause cancers of the vulva, vagina, penis,
anus, and certain head and neck cancers; specifically, the oropharynx, which includes the
back of the throat, base of the tongue and tonsils 36. As a result, more than 90% of
cervical and anal cancers, approximately 70% of vaginal, vulvar and oropharyngeal
cancers, and 60% of penile cancers are the result of a HPV infection 7. In particular, HPV
types 16 and 18 are associated with about 70% of cervical cancers, with type 16 having
the strongest evidence for overall carcinogenicity and types 6 and 11 are associated with
90% of genital warts 37.
Gardasil 9, the only HPV vaccine available for use in the United States, prevents
infection from these four types (16,18,6,11) and five additional cancer-causing types
(31,33,45,52 and 58). Therefore, of the total identified 13 HPV types there are five
remaining HPV types (35,39,51,56,59 and 66) associated with cervical cancer that need
vaccine development 38. There are numerous other individual reports of human
papillomavirus types in cancers of the esophagus, prostate, bladder, breast, lung and other
organ sites. With the exception of nail bed cancers, none of these reports show a
consistent association of the virus with the respective site. Therefore, although high risk
HPV types may sometimes cause cancers in atypical locations, the inconsistency of these
reports does not provide strong support for researching these additional locations39.
Many of the ongoing searches for novel HPV types use established consensus
primers in polymerase chain reactions. This somewhat allows for the detection of
partially homologous sequences because in theory HPV types not discovered by these
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primers or those very distantly related to a known type of this virus group, would likely
escape detection 39. The direct detection of HPV genomes and their transcripts could be
improved through hybrid testing procedures. However, new technical approaches that
might increase the sensitivity of detecting new HPV types need to consider the clinical
significance because not all HPV infections are persistent and lead to a clinically relevant
disease. The development of a new technical approach that determines if the presence of
multiple infections is a useful marker for persistent infection and the onset or progression
of disease would assist with clinical significance.
Current approaches to increase the clinical sensitivity are testing only for
clinically relevant high risk HPV types, adding a viral load measure and testing for high
risk HPV E6 and E7 transcripts 38. In spite of current technical limitations, a defining
characteristic of cancer associated with persistent infection by the high risk HPV types is
that viral genomes are commonly found integrated into the cancer cell genome, however,
minute viral variations may show risk differences that could distinguish molecular
mechanisms. It is already well established that while all the high-risk HPV types are
genetically related, they greatly differ in prevalence, evolutionary fitness and in risk of
causing precancer and cancer. HPV genetic variation represents slow evolutionary drift
and the HPV types are made up of phylogenetic variant lineage as well as sublineage
evolutionary clades that differ from each other by approximately 1% to 9% 28,34. These
minute viral variations may contribute to the increased number of identified HPV strains
and the corresponding number of carcinogenic strains.
Understanding the unique carcinogenicity of high-risk HPV types, such as
identifying patterns to explain the amino acid changes in HPV proteins, would be useful
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for vaccine development. The use of antibodies to inhibit protein function is a viable
option for treatment because viruses express proteins that are different from those
expressed by the cell and they are directly involved in causing disease. However, the
disease associated proteins resemble their normal cellular counterparts at most of the
sites, making the discovery of molecules that can specifically target disease associated
forms difficult. Specifically, one reason for the difficulty in targeting HPV infection is
because most papillomavirus proteins bind to cellular proteins instead of using their own
enzymatic activity to enact their effects. Alternatively, since E6 and E7 are co-expressed
in cancers from a bicistronic mRNA, RNA interference could be a promising approach
for vaccine development as well 29,40. Being immune to one HPV type may not prevent
the infection of another HPV type. Therefore, the ultimate prevention goal would be to
have a prophylactic vaccine that includes all carcinogenic HPV strains according to
potential genetic variation of HPV types and targets HPV proteins E6 and E7.
2.5 The Efficacy and Delivery of HPV Vaccination
Pressing questions related to HPV vaccination efficacy and delivery are who
should get the vaccine, is it safe, and is it effective. According to CDC the best age for
boys and girls to get the Gardasil vaccine is 11 to 12 years of age since children are not
yet sexually active at this age. Data suggests that 6% of US high school students had
sexual encounter before age 13. Also, research has suggested that girls who get
vaccinations at age 12-16 have significantly more antibody titers present in their blood
compared to older women favoring that the vaccinations be administered at an early age.
As more antibody research is done with boys, the central idea is to get people protected
against the virus before they encounter the virus for the first time. The vaccine can also
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be given as early as 9 years of age and is now approved by the U.S. Food and Drug
Administration (FDA) for men and women up to 45 years of age. Children who start the
series between 9 and 14 years of age should get two shots of the HPV vaccine six months
apart. Adolescents who start the series after their 15th birthday will require three doses of
the HPV vaccine, with the second dose 2 months after the first, and the third dose 6
months after the first. This same three dose schedule is recommended for adults and for
immunocompromised individuals 41,42.
Twelve years of monitoring and research have shown that the HPV vaccine is safe
and effective in large clinical trials and extensive post-licensure data further supports the
vaccine’s safety and efficacy. All of the HPV vaccines use virus like particles which
mimic the viral capsid but do not contain genetic material and are produced in biologic
systems, which have well established safety records. In the large licensing trials, baseline
HPV infection status was measured through serologic testing and DNA detection in
cervical specimens. Efficacy in the overall trial populations was consistently lower than
among those without baseline HPV infection. This revealed that many trial participants
were already sexually active and previously infected with vaccine HPV types; thus
emphasizing the importance of receiving vaccination before the onset of sexual activity to
maximize effectiveness 43. Since cancer registries do not routinely collect data on
whether HPV is in the cancer tissue, case-control studies are emphasized as opposed to
prospective cohort studies due to a larger number of invasive cancers that have been
evaluated 38. Clinical trial research continues to monitor and evaluate HPV vaccination
efficacy.
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Currently, there is no scientific evidence to associate the HPV vaccine with any
specific adverse event43–47. However, like any vaccine or medicine, HPV vaccines can
cause side effects. The most common side effects are pain, redness, or swelling in the arm
where the shot was given; dizziness, fainting, nausea, and headache 48. It was reported
that recipients of the 9-valent vaccine were slightly more likely to experience these side
effects than recipients of the quadrivalent vaccine (90.7% vs 84.9%) possibly due to
higher amounts of virus like particles and adjuvants in the 9-valent vaccine 10. In an
analysis of seven trials in which over 15,000 individuals received at least one dose of the
9-valent vaccine, serious adverse events occurred in less than 0.1%43. Some surveys of
parents of adolescent girls identified a concern the HPV vaccine to have a behavior
impact on sexual promiscuity. However, studies have not confirmed an association
between vaccination and increased sexual behavior 43. Additionally, multiple large
studies have provided evidence that the HPV vaccine is as safe as any other vaccination
and that those who receive this vaccine are not at a higher risk of any negative events
when compared to receiving any other vaccine immediately or in the long-term future49.
Therefore the cancer prevention benefits of HPV vaccination far outweigh the potential
risk of side effects 48.
Research shows that HPV vaccine protection is long-lasting. Current studies have
followed vaccinated individuals for 12 years and show that there is no evidence of
weakened protection over time. HPV vaccination research includes over 10 years of data
and continues to be monitored by the Centers for Disease Control and Prevention (CDC)
and the Food and Drug Administration (FDA)48. HPV vaccination has shown high quality
duration of protection for this 10 year time period even though the precise level of
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antibody needed for protection against infection is unknown 43. As a result, over 120
million doses of the HPV vaccine have been administered in the United States.
A potential clinical trial to further address HPV vaccine delivery would be one that
finds a biomarker related to immune response and host susceptibility to HPV. Focusing
on cervical cancer would provide an adequate source population because nearly all cases
of cervical cancer types are resultant of an HPV infection and the primary prevention
strategy against cervical cancer is HPV vaccination. Hispanic women have the highest
incidence rate of cervical cancer, however, the highest death rate from cervical cancer is
among African American women. In comparison to White women, African American
women are more likely to be diagnosed with cervical cancer. Of the known HPV strains
that are strongly associated with cervical cancer, it is unclear if these various strains are
significant to mortality. Research studies have indicated that biologic, socioeconomic,
cultural, environmental and other factors may affect cervical cancer incidence and
mortality 50. Therefore, the investigation of disparities in immunologic host susceptibility
factors due to ethnicity are of interest. The independent variable of interest would be the
clearance of high-risk HPV infection types by African American women and the
dependent variable of interest would be the mortality of African American women with
cervical cancer. The relationship between the clearance of high-risk HPV type infections
by African American women and the mortality of African American women with cervical
cancer, is potentially due to how the immune system responds to viral infections. Quach
et al investigated the differences in the transcriptional responses of Africans and
Europeans to immune stimulation. They found distinct differences among antiviral and
inflammation-related genes that significantly differed in responsiveness between Africans

22

and Europeans. Specifically, the master regulator, TLR1, controls the inflammatory
response in Europeans and contributes significantly to differences in the strength of the
inflammatory response between Africans and Europeans 51. This evidence provides good
support for genetic variants of immune responses. However, there does not seem to be
any exploration as to the TLR pathways that are activated and regulated in Africans for
their inflammatory responses. Also, the variants affecting immune responses in African
genomes are not discussed. Therefore, this evidence appears to be lacking sufficient
information on African genetic differences and regulatory variants to adequately
determine differences in host immune responsiveness between Africans and Europeans.
Banister et al (2015) investigated the persistence of high-risk HPV genotypes
between African American and European Women of College Age. They found that of the
2,121 clinic visits for the study, on 40% of them European American women were HPV
positive and on 51% of them African American women were HPV positive. For
European American women, 37.1% of the visits produced high risk HPV types and 8.7%
produced low risk HPV types. For African American women, 47.4% of the visits
produced high risk HPV types and 14.4% produced low risk HPV types. Using
multivariable analysis of the association between ethnicity and high-risk HPV infection,
African American ethnicity and lifetime number of sex partners was significant; thus,
indicating that clearance of high-risk HPV could be different between African American
and European American women. The required time for 50% of high-risk HPV infections
to clear was almost double the days for African American women compared to European
American women. African American women also had 1.61 times the odds of not clearing
a high-risk HPV infection compared to European American women. African American
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women had more abnormal Pap test results (ASCUS, LSIL, and HSIL) compared to
European American women and were significantly associated with an abnormal Pap test
result when the lifetime number of sex partners, HPV vaccine receipt and smoking were
controlled for. However, high risk HPV type was significantly associated with an
abnormal Pap test result when ethnicity, the lifetime number of sex partners, HPV
vaccine receipt, and smoking were controlled for. This suggests that the high-risk HPV
status is the reason for differences in abnormal Pap test results between African
American and European American women. Therefore, the increased risk of an abnormal
Pap test result and the increased probability of being high risk HPV positive is potentially
due to persistent infection of high risk HPV rather than differences in exposure to HPV
52

. This evidence provides good support for increased cervical cancer incidence in

African American women. However, there does not seem to be any exploration into the
connection of the high-risk HPV type and increased mortality rates of African American
women with cervical cancer.
Clifford, Franceschi, Diaz, Muñoz and Villa (2006) investigated the distribution of
HPV type in women with and without cervical neoplastic diseases. After comparing a
pooled analysis and a meta-analysis, the most common HPV types in invasive cervical
cancer were HPV-16,-18,-33,-45,-31,-58,-52,-35,-59,-56,-51,-39,-68, and -73. The most
common HPV types in high grade lesions (HSIL) were HPV-16, -31, -58, -18, -33, -52, 35, -51, -56, -45, -39, -66 and -6. The most common HPV types in low grade lesions
(LSIL) were HPV-16, -31, -51, -53, -56, -52, -18, -66 and -58. The most common HPV
types in women with atypical squamous cells of undetermined significance (ASCUS)
were not reportable because no meta-analysis on HPV type specific prevalence existed at
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that time. The most common HPV types in women without cytological abnormalities
were HPV-16, -42, -58, -31, -18, -56, -81, -35, -33, -45 and -52. The shifts in HPV type
distribution across cervical lesions of increasing severity show that HPV types 16, 18 and
45 are significantly more common in squamous cell carcinoma (SCC) than HSIL, HPV
types 16 and 18 are more common in SCC than LSIL but other HPV types are more
frequent in HSIL and LSIL than SCC. These differences indicate that HPV type can
differ in the risk of developing cervical cancer from HSIL 53. This evidence provides
good support for the distribution of HPV type related to LSIL, HSIL and cervical cancer.
Their findings allow for inference of HPV types that may be connected to cervical cancer
mortality. However, there does not seem to be any exploration into HPV type distribution
by ethnicity. Even though geographical variations were taken into consideration, North
America was not represented in the pooled analysis from the International Agency for
Research on Cancer (IARC) but was stated to be similar to Europe in terms of proportion
to HPV-16 infection. This clarification is important because a woman of African descent
living in North America is different from a woman of African descent living in Europe.
Therefore, based on the literature, early inflammatory responses may be critical for
initiating a strong defense against HPV infection, however, there are genetic variants of
immune responses. It has been shown that for African American women, the increased
risk of an abnormal Pap test result and the increased probability of being high risk HPV
positive is potentially due to persistent infection of high-risk HPV. Meanwhile, the cause
for increased mortality among African American women with cervical cancer is
unknown. For this reason, the identification of HPV type in African American women
with cervical cancer is needed when investigating their death because HPV type can
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differ in the development of cervical cancer even from HSIL. My hypothesis is that if the
high-risk HPV types of African American women with cervical cancer were identified
and cleared or prevented due to the improved efficacy of HPV vaccination, then their
mortality rates would decrease. This is of particular interest because cervical cancer
mortality rates are especially high in African American women in the rural South, but not
for African American women in the West.
For African American women in the South, some shared characteristics are that the
poverty levels are above the national average, educational level is low, geographic
isolation, lack of transportation, greater exposure to environmental and occupational
hazards, poor housing, distrust of the government and mainstream medicine and a
tenacity to sustain themselves in harsh living conditions50. Retrospective reviews of
women diagnosed with cervical cancer indicate that 50% to 70% of them did not have a
Pap test within five years prior to diagnosis or they never had been screened 50. Many
women living in areas with high rates of cervical cancer mortality rely on publicly funded
programs for their health care; therefore addressing cervical cancer mortality could serve
as an indicator of an inefficient health care system concerning issues of medical care
access, cultural issues, health communication and health education that
disproportionately affect poor and underserved women. Areas with high cervical cancer
mortality also experience high mortality rates for breast cancer, colon cancer, heart
disease, stroke, infant mortality and other conditions that improve with regular screening
or early intervention 50. Because cervical cancer mortality is an avoidable cause of death,
the overall health status of these geographic regions with high cervical cancer mortality
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includes additional parameters of critical importance for improving the efficacy and
delivery of HPV vaccination.
2.6 Using Geospatial Data to Improve HPV Vaccine Delivery
HPV vaccination data measurements associated with geographic locations are
becoming more available from immunization registries. However, the fundamental nature
of spatial data imposes some analytic challenges that should be considered with HPV
vaccine delivery. When using spatial methods in epidemiologic research there are
positive and negative aspects of spatial data that contribute to the accuracy of estimation.
Measuring distance from one location to resources is frequently used to estimate
environmental exposure. For example, the distance from a residence to a health
department clinic or pharmacy to receive the HPV vaccine could be used to estimate
environmental vaccination access. However, straight-line distance can be a poor proxy
for estimating access if there are no direct roads or other means of traveling to a
particular location54.
When considering the relationship of spatial features geographical information
systems (GIS) it is important to use topology. GIS topology is broadly defined as the
spatial relationships between adjacent or neighboring features. Adjacency is a type of
spatial relationship where two or more polygons share a side or a boundary. For example,
Georgetown, Berkeley, Dorchester and Colleton counties are all adjacent to Charleston
county. Neighborhood is a defined shape or area in which only the cells that have their
cell centers within the neighborhood are considered part of the neighborhood. There
should be no overlapping features. For example, a rectangle neighborhood can be created
by specifying the height and width in map units such as degrees, meters or feet. So, in
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measuring the neighborhood of Mt Pleasant, only include the land area of 116.8 km2
would be included. Adjacency and neighborhoods are effective for modeling spatial
relationships and the analyses of contiguity and connectivity. However, these data are
inherently static and do not allow for real world representation of spatial changes over
time. As a result, boundary problems such as edge effects must be considered. Edge
effects are evidenced when the boundaries of a study area affect a given spatial
measurement and lead to inaccurate estimates. This happens when the study area is
defined by a border that does not prevent travel, therefore the geographic distribution of
variables within an area may in fact extend beyond the border. Not accounting for edge
effects introduces biases and under-reporting. For example, Berkley county may show a
low count of administered HPV vaccination doses that they have administered, but this
does not mean that fewer adolescents are receiving the HPV vaccine because in fact,
many adolescents could be traveling to Charleston county to receive their vaccine55.
Spatial autocorrelation measures the correlation of a variable with itself through
space and refers to the relationship/pattern that variables of proximal entities will share
more similar values than distant entities. It is expected that the level of spatial
autocorrelation diminishes as a function of distance between two regions, unless there is
some reason for similarity due to some other associated factor56. However, this assumes
initial independence of data, which may not be appropriate. For example, the spatial
autocorrelation between HPV vaccination rates in urban counties is assumed to be the
same in the state of South Carolina. This would mean that the relationship between HPV
vaccination rates was purely a function of distance between the counties and not relative
to their location. Since a map is the representation of various locations, it can be defined
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as a collection of spatially defined objects. The modifiable area unit problem (MAUP) is
the inconsistency in how the map scale can yield different results when aggregated in
different ways. Therefore, the changes the scale makes on the analysis needs to be
quantified, otherwise variable measures could be underestimated. If results are
significantly different, then the scale may need to be modified so that the results are more
consistent. Scale refers to the ground area of the map and can be described as large or
small. For example, a county level map of South Carolina is large scale representation
compared to a state level map of South Carolina, which is small scale representation.
When administered HPV vaccination doses are aggregated on a small scale (state level),
areas with decreased HPV vaccination access are underestimated56.
2.7 Insufficient Data
Studies have shown that Immunization Information Systems also referred to as
immunization registries, are effective in improving vaccination related activities to
increase vaccination rates and reduce risk for vaccine preventable diseases4,57. However,
in the literature there is a gap between national state level vaccination data and local level
adolescent vaccination data often tracked by state immunization registries19,21,58–61.
Hence, within state variability has not been commonly studied. Additionally, there is very
little information about how vaccination is affecting the prevalence of HPV-associated
cancers in rural areas. These areas may be medically underserved, have high rates of
cervical cancer, and low rates of HPV vaccination20. The National Immunization Survey
(NIS) provides data on HPV vaccination rates by state but there is less detailed
information on the prevalence of HPV-associated cancers within states or how changing
vaccination rates affects the prevalence of HPV-associated cancers directly in each
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region. With the limitation of state level data, the reasons for geographic vaccination
disparities are currently not well understood and this may be due to the lack of state
immunization registry data at the local level. As a result, these local areas may continue
to be a source of geographical disparities in HPV-associated cancer incidence as well 20.
Therefore, more data are needed to evaluate impact of HPV vaccination in smaller
geographic areas. With improved tools for HPV vaccination surveillance, the impact of
county level vaccination programs and policies on population level vaccination and the
prevalence of HPV-associated cancers can be evaluated better.
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3.0 SIGNIFICANCE & INNOVATION
3.1 Clinical and Public Health Significance
The occurrence of HPV associated cancers varies by cancer type, sex and
race/ethnic group and is estimated to have a combined cost of $8 billion per year in the
United States4. Approximately 44,000 new cases of HPV-associated cancers occur in the
United States each year affecting women and men. HPV associated cancers most
commonly occur in the cervix among women and in the oropharynx (back of the throat,
including the base of the tongue and tonsils) among men62. Among these cancer types, it
is estimated that 35,900 cancers (79%) were actually caused by HPV during 2011-2015
and that 31,200 of these cancers could have been prevented by the 9-valent HPV
vaccine62. However, as of 2019 no state in the United States has reached the Healthy
People 2020 HPV vaccination goal of 80% coverage and HPV vaccination coverage
varies substantially by state15,63.
The between state variation of HPV vaccination may be due to insufficient HPV
surveillance. Unlike other reportable sexually transmitted infections in every state, HPV
is not a nationally notifiable condition because HPV infections are too common.
However, the delivery of HPV vaccinations is monitored. Frequently health-care claims
data from adolescents and adults with employer-provided private health insurance in the
United States are used to examine the population effectiveness of HPV vaccinations on
HPV infections64. Additionally, in some states, all health care providers are required to
report the administration of all vaccines to state immunization registries, however, the
tracking and reporting of vaccine delivery is inconsistent among state health departments.
A consistent source of data is the National Immunization Survey–Teen (NIS-Teen),
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which is an annual survey that estimates vaccination coverage among adolescents aged
13–17 years in the 50 states, the District of Columbia (DC), selected local areas, and
territories. However, NIS-Teen data do not report HPV vaccination below the state level
whereas state immunization registries are able to. Therefore, using state immunization
registries is a critical step in overcoming the challenge of HPV vaccination surveillance
beyond the state level. This research quantified HPV vaccination coverage at the county
level using administered doses of the HPV vaccine collected by GA and SC state
immunization registries.
The clinical significance of monitoring HPV vaccination is that immunization
coverage rates are a key indicator of overall community health65. The extent to which
health departments deliver immunization services is associated with multiple components
of quality public health services such as vaccine supply, surveillance, advocacy and
communication and logistics. As a result, HPV vaccination coverage rates at the county
level are impacted by the equity of access to health care services provided by health
department clinics. Therefore, examining indicators of HD clinic access offers more
insight into why HPV vaccination coverage rates differ by locality even though HDs
implement many of the same immunization services. For example, HDs must conduct
more quality assessment visits to providers enrolled in the VFC program. Nationally,
under the VFC program, the Center for Disease Control (CDC) purchases vaccines at a
discount and distributes them to grantees, such as state HDs and certain local and
territorial public health agencies. These grantees distribute the vaccines at no charge to
private physicians' offices and public health clinics that are registered as VFC providers.
Because the federal government pays for the vaccine, providers are not paid for the cost
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of the vaccine product. Instead, they are paid an administration fee for the costs that the
provider incurs in administering the vaccine. For children enrolled in Medicaid, the
Medicaid program pays the vaccine administration fee. For uninsured and underinsured
children enrolled in VFC, the parents are billed for the administration fee and the
administration fee varies by state66.
3.2 Innovation
GA and SC are both in public health region IV and therefore share the same
regional office for programs and policies through the U.S. Department of Health and
Human Services (HHS) (Figure 1). Despite the difference in the number of counties, GA
and SC share similar population demographic characteristics67–69 (Figures 2, 3, Table 1).
The estimated vaccination coverage rates in the public health region IV have shown GA’s
Tdap and HPV vaccination rates to consistently be near or exceed the national average
from 2016 to 2018. Conversely, during this same time period, SC was consistently below
the national average with the lowest HPV vaccination coverage estimate in the United
States in 2016 according to the National Immunization Survey – Teen data70. Systematic
underuse of services that impact health by populations that share similar demographic
characteristics may indicate a problem with equity of access11. Hence, access may be a
significant driver of the different vaccination rates between GA and SC. To explore these
differences at the county level GA has comprehensive adolescent HPV vaccination data
available at the zip code level that can be aggregated to the county level using Zip Code
Tabulation Areas but SC does not. Therefore, GA’s availability of county level HPV
vaccination data and similar population demographics to SC, supports GA as a suitable
model state for increasing SC’s HPV vaccination coverage rates.
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This research innovatively 1) predicted county level HPV vaccination coverage
using public health surveillance data previously collected by two different state
immunization registries, census tracts and the department of transportation, instead of the
exclusive use of national self-report surveys. With these data we 2) geographically
characterized HPV vaccination coverage data at the county level using adolescents who
have received the school mandated Tdap vaccine as the sample population. This sample
population controlled for many sources of confounding such as parents who oppose
vaccines, children with medical conditions preventing them from receiving vaccines, and
those without any access to vaccines. This research 3) assessed indicators of health care
access using health care utilization properties related to the health care settings 11: the
number of public and private clinics and the number of health department clinics with
VFC provider registration. This research 4) assessed indicators of health care access
using a health care utilization property related to health equity71: public transit
transportation. Using an adapted model of access to personal health care services from
the Institute of Medicine (Figure 4) as our conceptual framework, this research
innovatively 5) examined the effect of key factors associated with HPV vaccination to
highlight counties with HD clinic access problems resulting in the poor health outcome of
low HPV vaccination coverage. The mediators in this conceptual framework of provider
recommendation, uptake and delivery of HPV vaccine and parental hesitancy were not
adjusted for in analyses in order to examine the total effect and any effect of HPV
vaccine delivery in HD clinics on HPV vaccination coverage.
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3.3 Table
Table 1. Population Demographic Characteristics
Georgia
Counties
159
HPV vaccination coverage trend:
≥ 1 dose, all adolescents aged 13-17*
(United States overall)*
2016 (60.4 %) 67.30%
2017 (65.5 %) 64.30%
2018 (68.1 %) 68.10%
Tdap vaccination coverage trend:
≥ 1 dose, all adolescents aged 13-17*
(United States overall)
2016 (88.0 %) 92.80%
2017 (88.7 %) 93.30%
2018 (88.9 %) 94.20%
+
Race Ethnicity
Black/African American 31.30%
White 52.80%
Asian 4.20%
Hispanic 9.60%
American Indian/Alaskan Native 0.50%
Native Hawaiian/Other Pacific Islander 0.10%
Below 18 years of age+
24.10%
Education+
Highschool graduation 81%
Some College 63%
Median Household Income+
Uninsured children+
Children in poverty+
Living in rural area+

$56,100
7%
22%
24.90%

South Carolina
46

44.20%
59.60%
63.70%

77.50%
89.40%
88.90%
26.80%
63.80%
1.70%
5.70%
0.50%
0.10%
22.00%
84%
62%
$50,700
4%
22%
33.70%

Data Sources:
* (Walker et al., 2019)
+ (“County Health Rankings & Roadmaps,” 2019)
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3.4 Figures
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5.1 Abstract
Objective: To characterize counties in GA by quantifying administered doses of the HPV
and Tdap vaccines collected by the state health department immunization registry and
indicators of HD clinic access.
Methods: Using a cross sectional study design, secondary data were collected from 2010
US Census, the Georgia Department of Public Health, Georgia Registry of Immunization
Transactions and Services (GRITS), and the Georgia Department of Transportation for
the years 2016 to 2018 for all 159 counties of GA. The study population was all male and
female adolescents aged 13-17. The number of administered doses of the HPV vaccine
and the number of administered doses of the Tdap vaccine were modeled in relation to
number of private and public HD clinics, number of HD clinics registered in the VFC
program and the availability of public transportation using Poisson regression, negative
binomial regression and Bayesian spatial analysis.
Results: Choropleth maps showed similar clustering patterns between administered doses
of the HPV vaccine and Tdap vaccine and increased counts of administered vaccine
doses in counties with both public and private clinics. Administered doses of HPV
vaccine were found to exhibit spatial dependence across counties. Accounting for spatial
dependence, the availability of public transit has a significant positive effect on
administered doses of HPV vaccine. Administered doses of the Tdap vaccine were also
found to exhibit spatial dependence across counties. Accounting for spatial dependence,
the number of private health department clinics has a significant positive effect on
administered doses of the Tdap vaccine.
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Conclusions: This study calls attention to the need for maps at the county level to show
vaccination variability and clustering patterns to provide additional insights on the access
to health care. Using Bayesian spatial models to account for the effect of spatial
variability on HPV vaccine and Tdap vaccine dose administration between counties
changed the significant effects of HD clinic access on HPV vaccine and Tdap vaccine
dose administration to non-significant. This suggests that spatial statistical models are
needed to accurately identify and estimate factors associated with administering doses of
the HPV and Tdap vaccines. Future work is needed to further examine the utilization of
HPV vaccination services among urban groupings.

Keywords: Choropleth maps, HPV vaccine, Tdap vaccine, Bayesian spatial models
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5.2 Introduction
In its 2012-2013 report, the President’s Cancer Panel concluded that underuse of
human papilloma virus (HPV) vaccines was a serious but correctable threat to progress
against cancer1,2. Approximately 91% of cervical and anal cancers, 75% of vaginal, 69%
of vulvar, 70% oropharyngeal cancers, and 63% of penile cancers are the result of an
HPV infection3,4. During 2012-2016, an estimated average of 34,800 HPV-attributable
cancers were diagnosed each year. Among these estimated cancers, 92% were
attributable to the HPV types that are included in the 9-valent HPV vaccine and could
have been prevented if HPV vaccine recommendations were followed5. The 9-valent
vaccine, Gardasil 9, was studied in clinical trials with more than 15,000 females and
males and found to be safe and effective6. Currently, the HPV vaccination coverage rate
is increasing at national and state levels. As of 2019, about half of U.S. adolescents aged
13-17 are fully vaccinated (54.2%) and 71.5 % of them have received at least one dose of
the HPV vaccine7. At the state level, South Carolina has impressively improved from a
rate of 44.2% in 2016 for adolescents receiving at least one dose of the HPV vaccine,
which was substantially below the national average of 60.4% (44.2%) to matching the
national average (71%) in 20197. However the overall national goal is to increase HPV
vaccination coverage levels for adolescents to 80%8.

Efforts to increase HPV vaccination are supported by resources often
administered and utilized at the county level through state Health Departments (HD) such
as childhood and adolescent vaccinations administered by school nurses and at public or
private health clinics, community education and outreach, vaccine program enrollment,
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and immunization registry reporting. Health care utilization can be determined by
whether the provided health care can be accessed9. Access to health resources and quality
healthcare services is an important determinant of health 10 and certain barriers such as
physician shortage, lack of transportation, and insurance coverage can make gaining
access difficult. Therefore, the underutilization of the HPV vaccine may be due to
inequitable access. Equitable access to health care requires that everyone is able to
receive an adequate level of care and resources without excessive burdens11.
Maximizing access to HPV vaccination service was quantified as 80%
vaccination coverage by Healthy People 202012. As of 2019 no state in the United States
reached the Healthy People 2020 HPV vaccination target of 80% coverage and HPV
vaccination coverage varies substantially by state7,12,13. The between state variation of
HPV vaccination may be due to the absence of standardized monitoring of HPV
infections. Unlike other reportable sexually transmitted infections in every state, HPV
infections and most HPV-associated conditions are not nationally notifiable14. Since HPV
infections are too common to be reportable, making HPV-associated conditions
reportable would increase the extent of public health surveillance which is useful for
measuring the need and effect of HPV vaccination interventions and for targeting
resources. Instead, health-care claims data from adolescents and adults with employerprovided private health insurance in the United States are used to examine the population
effectiveness of HPV vaccinations on HPV infections15. The HPV vaccine is also not a
required immunization for school attendance like the Tetanus, diphtheria, and pertussis
(Tdap) vaccine. Therefore, strategically allocating HD resources is necessary to improve
HPV vaccination coverage16 and address the President’s Cancer Panel’s third goal of
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maximizing access to HPV vaccination services1. An essential tool for allocating HD
resources is the state immunization registry. GA’s state HD immunization registry has a
surveillance system that is able to monitor at the county level how many of their clinics
are public, private, registered with the Vaccine For Children (VFC) program and the
administered doses of the HPV and Tdap vaccine per clinic. This has contributed to
Georgia’s vaccination coverage trend of adolescents receiving at least one dose of the
HPV vaccine staying close to the national average since 201613 (Table 1). However,
some states to do not have county level HPV vaccination coverage data available and this
is a major obstacle to effectively monitor HD resource utilization to increase HPV
vaccination.
Therefore, the objective of this study was to characterize counties in GA by
quantifying administered doses of the HPV and Tdap vaccines collected by the state HD
immunization registry and indicators of HD clinic access. The rationale is based on the
ability to evaluate the county level geospatial distribution of administered HPV vaccine
doses compared to administered Tdap vaccine doses with indicators of HD clinic access
to better understand county level access to adolescent HPV vaccination. The hypothesis
is that in GA, administered doses of the HPV vaccine and the Tdap vaccine are associated
with indicators of HD clinic access.
5.3 Methods
Data
Using a cross sectional study design, secondary data were collected from 2010 US
Census, the Georgia Department of Public Health, Georgia Registry of Immunization
Transactions and Services (GRITS), and the Georgia Department of Transportation for
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the years 2016 to 2018 for all 159 counties of GA. The study population was all male and
female adolescents aged 13-17 in GA. Differences in HD clinic access in relation to
administered doses of HPV and Tdap were assessed. Indicators of HD clinic access were
defined as the number of available public and private clinics, the number of HD clinics
with Vaccine For Children (VFC) provider registration, and the availability of public
transportation in the county. Administered doses were defined as greater than or equal to
one vaccine dose given to adolescents aged 13 -17 from public and private clinics sites
regardless of their VFC program participation and reported to the state immunization
registry. The number of administered HPV and Tdap vaccine doses, the number of public
and private HD clinics, and the number of clinics registered in the VFC program were
collected by zip code and aggregated to the county level using Zip Code Tabulation
Areas (ZCTAs). The availability of public transportation was defined by the presence of
public transit routes inclusive of the metro Atlanta region, only rural, only urban, both
rural and urban, and city only transit identified in each county by the Georgia Department
of Transportation. Choropleth maps17 of administered HPV and Tdap vaccine doses and
indicators of access to HD clinics at the county level were created SAS statistical
software version 9.4 18.
Statistical Modeling & Analyses
Two dependent variables were individually modeled as outcomes: the number of
administered doses of the HPV vaccine and the number of administered doses of the
Tdap vaccine. These dependent variables were modeled in relation to the explanatory
variables defined as indicators of HD clinic access: number of private and public HD
clinics, number of HD clinics registered in the VFC program and the availability of
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public transportation. For both outcomes three statistical methods were used: Poisson
regression, negative binomial regression and Bayesian spatial analysis. While exploring
the data with Poisson regression, overdispersion was detected so negative binomial
regression was used for modeling19. Fixed effects only were evaluated first, and a
backward stepwise selection method for selection of explanatory variables via the Akaike
Information Criterion (AIC). To account for the non-spatial random effect of county,
random intercept negative binomial models were evaluated using backward stepwise
selection via AIC. Initially, the model was fit maintaining all the explanatory variables.
The final model retained all variables that were statistically significant at p<0.05.
Likelihood ratio tests were used to compare models, with the best model fit determined
by AIC.
Systematic spatial variation also known as spatial autocorrelation in the counts of
administered doses of the HPV vaccine and the Tdap vaccine were assessed using
Moran’s I20. Positive values of Moran’s I indicate that nearby counties tend to exhibit
similar counts of administered HPV and Tdap vaccine doses, while negative values
indicate dissimilar counts. In the data used for this study the existence of a significant
spatial autocorrelation points to the necessity of using Conditional autoregressive (CAR)
models to represent this spatial autocorrelation21. CAR models smooth noisy estimates by
pooling information from neighboring regions. A proportion of this spatial
autocorrelation may be modeled by known covariate risk factors in a regression model,
but it is common for spatial structure to remain in the residuals after accounting for these
covariate effects. This residual spatial autocorrelation can be influenced by unmeasured
confounding, neighborhood effects, and grouping effects. The most common remedy is to
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augment the linear predictor with a set of spatially autocorrelated random effects, as part
of a Bayesian hierarchical model. These random effects are typically represented with a
conditional autoregressive prior, which generates spatial autocorrelation through the
adjacency structure of the areal units21.
For the spatial analysis two Bayesian models were compared: Besag-York-Mollié
(BYM)22 and Leroux23 with Poisson family distributions. The BYM model uses a
parameter for structured spatial random effects and a parameter for unstructured spatial
random effects to account for over-dispersion not modelled by the Poisson variates.
When the observed variance is not fully explained by the spatial structure of the data, the
independent error term will account for the rest24. However, the BYM model only
assumes a spatially structured component, so the spatial and non-spatial random effects
cannot be identified independently from each other. This results in the non-spatial
random error or pure overdispersion being modelled as spatial correlation25. The Leroux
model is a variation of the BYM and CAR models in which there is only one spatial
random effect parameter for each area that includes characteristics of both structured and
unstructured spatial random effects26. For this illustration, the random effect terms can be
interpreted as the county effect on HPV vaccine and Tdap vaccine dose administration.
To find the best fitting Bayesian model the Deviance Information Criterion (DIC)
was used. Each spatial model was run to convergence based on multiple chain diagnostics
using the Brooks-Gelman-Rubin statistics27. In the converged sample DIC was
monitored. Convergence usually took place within 1,000 iterations and inference was
based on a chain length of 1,000 after convergence. Regression analyses and estimation
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of the model parameters carried out with MCMC simulation techniques were
implemented in R V.3.6.3 software packages28.
5.4 Results
Data Maps
Choropleth maps are thematic maps in which areas are colored or patterned to
indicate differences of quantity in those areas17. In this study they show the geospatial
distribution of the aggregated counts of administered does of the HPV vaccine and Tdap
vaccine, counts of HD private clinics, counts of HD public clinics, and access to public
transportation for each county (Figures 1-5). The clustering patterns of administered
doses of the HPV vaccine and the Tdap vaccine are both similar with increased counts in
the Atlanta (ATL) region. There is not a defined clustering pattern with the quantity of
administered vaccine doses in counties with access to public transportation. However,
there is a pattern of increased counts of administered vaccine doses in counties with both
public and private clinics.
HPV Outcome
The fixed effects negative binomial model was fit maintaining all of the
explanatory variables. None of the indicators of HD access variables were statistically
significant at p-values less than 0.05. The non-spatial random intercept negative binomial
model, to account for correlations within county, was fit initially with all of the
explanatory variables. The variable of HD clinics registered in the VFC program was
highly correlated with private HD clinics (r = -0.961) and therefore dropped from the
model. The remaining explanatory variables of private HD clinics, public HD clinics and
the availability of public transportation were all statistically significantly associated with
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counts of administered HPV doses (Table 2). These estimates can be interpreted as 1) a
one unit increase in the number of private HD clinics increases the expected counts of
administered doses of HPV vaccine by 1.08 times for adolescents in the same county and
holding all other variables in the model constant; 2) a one unit increase in the number of
public HD clinics increases the expected counts of administered doses of HPV vaccine by
1.17 times for adolescents in the same county and holding all other variables in the model
constant; and 3) having access to public transportation increases the expected counts of
administered doses of HPV vaccine by 1.63 times for adolescents in the same county
compared to not having access and holding all other variables in the model constant.
Using Moran’s I, the hypothesis that the administered doses of the HPV vaccine
are randomly distributed across counties following a completely random process was
rejected at the 0.05 level of significance. Thus, suggesting that the spatial distribution of
administered HPV vaccine doses are more spatially clustered than would be expected if
the underlying spatial distribution was random. Figure 6 shows a scatter plot of the
average sum of total administered doses of HPV vaccine for each county and Moran's I
coefficient (I=0.393) as the slope of the line. The positive (upward) slope suggests that as
the sum of administered HPV vaccine doses of a county increases, so does the sum of its
neighboring counties.
Using the statistically significant explanatory variables in the negative binomial
random effect model, comparison of the different Bayesian models showed the Leroux
model was the best model (DIC = 1783.6). From the Leroux model posterior estimates
for the parameters and measures of interest were obtained, including medians and 95%
credible intervals. Estimates for the best-fitting Leroux CAR model are shown in Table 3.
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Since the Leroux model showed evidence of convergence via the Potential Scale
Reduction Factor (PSRF) of 1.2 with Gelman and Rubin's Convergence Diagnostic, it can
be inferred that the availability of public transit has a significant positive effect on
administered doses of HPV vaccine and that there is no significant effect of private HD
clinics, and Public HD clinics on increasing administered doses of HPV vaccine.
Tdap Outcome
With the fixed effects negative binomial model, it was initially fit maintaining all
of the explanatory variables. In that analysis, only the number of private HD clinics was
statistically significant with a p-value less than 0.05. However, to account for correlations
within county, a non-spatial random effect negative binomial model was fit using all
explanatory variables. The number of HD clinics registered in the VFC program was
highly correlated with the number of private HD clinics (r = -0.976) and therefore
dropped from the model. Of the remaining explanatory variables, the number of private
HD clinics and access to public transit remained statistically significant (Table 2). These
estimates can be interpreted as a one unit increase in the number of private HD clinics
increases the expected counts of administered doses of Tdap vaccine by 1.09 times for
adolescents in the same county and holding all other variables in the model constant.
Similarly, having access to public transportation increases the expected counts of
administered doses of Tdap vaccine by 1.38 times for adolescents in the same county and
holding all other variables in the model constant. The best negative binomial regression
model was the fixed effect model (AIC = 2630.12) (Table 2). However, a likelihood ratio
test comparing the final fixed effects and the final random intercept model showed that
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the random intercept model is statistically more beneficial with the access to public
transit variable and the county effect included (p-value = 0.004).
Using Moran’s I, the hypothesis that the administered doses of the Tdap vaccine
are randomly distributed across counties following a completely random process was
rejected at the 0.05 level of significance. Thus suggesting that the spatial distribution of
administered Tdap vaccine doses are more spatially clustered than would be expected if
the underlying spatial distribution was random. Figure 7 shows a scatter plot of the
average sum of total administered doses of Tdap vaccine for each county and Moran's I
coefficient (I =0.4107) as the slope of the line. The positive (upward) slope suggests that
as the sum of administered Tdap vaccine doses of a county increases, so does the sum of
its neighboring counties.
Using the statistically significant explanatory variables in the negative binomial
random intercept model, comparison of the different Bayesian models showed the Leroux
model to be the best model (DIC = 1710.35). From the Leroux model posterior estimates
for the parameters and measures of interest were obtained, including medians and 95%
credible intervals (Table 5). Since the Leroux model showed evidence of convergence via
the Potential Scale Reduction Factor (PSRF) of 1.3 with Gelman and Rubin's
Convergence Diagnostic, it can be inferred that there is significant positive effect of the
number of private HD clinics on increasing administered doses of Tdap vaccine, and the
accessibility of public transit has no significant effect on administered doses of Tdap
vaccine.
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5.5 Discussion
Interpretation
In this study the counties of GA were characterized based on the quantity of
administered doses of the HPV vaccine, the Tdap vaccine and indicators of HD clinic
access using choropleth maps. Mapping county level counts provides greater
understanding of the trends and variability in patterns not possible by examination of
direct national and state level estimates. This was shown with no clustering pattern of
administered doses across counties with public transit services. These results are novel in
showing HPV and Tdap vaccination variability at the county level. Also, at the county
level there were clustering patterns of higher counts of administered vaccine doses in the
ATL region. These results were expected and support a common vaccination trend often
seen at the state level due to the large urban demographic. Additionally, mapping county
level vaccine counts can help highlight areas where HPV and Tdap vaccination coverage
may be higher or lower than the national average and provide additional insights on the
access to health care. This was shown with the clustering pattern of increased counts of
administered doses in counties with both public and private clinics. This pattern is
expected since health care services can be provided through public and private providers
serviced by the HD. Public health care is usually provided by the government through
national healthcare systems. Private health care can be provided through for profit
hospitals and self-employed practitioners, and “not for profit” non-government providers,
including faith-based organizations.29 However, our results also show that there was a
clustering pattern of less administered doses of HPV and Tdap vaccines in counties
where there were fewer private health clinics. These results suggest further examination
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into the number of HPV and Tdap vaccines ordered from public and private health clinics
serviced by the HD to clarify the reduced number of administered vaccine doses.
The patterns seen in our maps were supported by our statistical analyses. Both
administered doses of the HPV vaccine and the Tdap vaccine were significantly
associated with indicators of HD clinic access. However, to account for extra uncertainty
and inherent spatial autocorrelation, Bayesian spatial models were used because
administered doses of the HPV vaccine and the Tdap vaccine were found to exhibit
strong spatial dependence. Using these models to account for the effect of spatial
variability on HPV vaccine and Tdap vaccine dose administration between counties
changed the significant effects of HD clinic access on HPV vaccine and Tdap vaccine
dose administration to non-significant. This suggests that spatial statistical models are
needed to accurately identify and estimate factors associated with administering doses of
the HPV and Tdap vaccines in GA.
In relation to public health efforts, HPV vaccination coverage is lower than Tdap
vaccination coverage at the national and state level. This study showed that the inclusion
of the spatial random effect at the county level explains additional differences in HPV
and Tdap vaccine dose administration. Specifically, these results indicate that spatial
variability between counties and public transit access affect HPV vaccine dose
administration. Whereas, spatial variability between counties and the number of HD
private clinics affect Tdap vaccine dose administration. Therefore, public health
practitioners should be attentive to the differences and similarities of resources and
demographics between counties. These results are similar to previous studies that found
that HPV vaccination rates vary geographically30. Other studies have also demonstrated
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that HPV vaccination has a strong spatial dependence when identifying and estimating
factors associated with HPV vaccine uptake16 and that spatial accessibility to vaccination
providers increases overall vaccination31. Our results differed from a previous study that
found overall geographic access measures of travel distance and public transportation to
clinics were not significantly associated with vaccine initiation32. However, this
difference may be due to the limitation of the study sample to an urban area.
Limitations
There are limitations to acknowledge in this study. First, not all clinic sites are
represented because not all providers administer vaccinations, but these data do represent
all clinics who offer vaccination. Administered vaccine doses are only from clinic sites
that report to the state’s immunization registry. As such, there may be vaccination doses
administered that are not accounted for and would result in an underestimation of HPV
and Tdap vaccination delivery and coverage. Second, with administered dosing data is
that it is not possible to differentiate whether a dose was given to initiate or complete an
HPV vaccination series due to the fact that the immunization registry is not linked with
vital records. However, there are also several strengths to this study. This study is one of
the first studies to look at the aggregated counts of HPV vaccine and Tdap vaccine dose
administration at the county level as a proxy measure of HPV vaccination coverage.
These county level maps can used by practitioners and public health officials as baseline
visuals for further investigation of where clinics are not administering doses of the HPV
and Tdap vaccines. These results highlight where additional resources from HDs in GA
may be needed to improve the administration of HPV vaccination. Additionally, these
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results can be generalized to other states that have similar decentralized governance
structures like GA because of how vaccination health resources are administered.
Conclusion
Overall, reaching 80% HPV vaccination coverage among U.S. adolescents is an
attainable goal. However more information is needed beyond data at the national and
state level. This study showed the importance of considering spatial variation at the
county level when investigating HPV and Tdap vaccine dose administration. Mapping
spatial patterns provides a visual context to data that is helpful for informing the
development of public health interventions and guiding the provision of health services.
Additionally, mapping data can be useful as an advocacy tool for documenting how poor
public health infrastructure contributes to poor health outcomes to support improving
healthcare administration and public health infrastructure.
The need for public health interventions focused on HPV vaccination was
emphasized in early 2020 when the coronavirus disease 2019 (COVID-19) pandemic
changed the way health care providers operate and provide routine and essential
vaccination services. Like dose administration, vaccine orders are another proxy measure
for vaccination coverage33. Examination of VFC provider ordering data showed that
vaccine orders for HPV vaccine and Tdap vaccine decreased in mid-March when
COVID-19 was declared a national emergency. Therefore, public health interventions to
ensure that routine vaccination services for adolescents are maintained is essential to
continue progress in protecting communities7. To do so, future work is need with small
area studies. The collection of data at local levels such as ZIP code could help pinpoint
areas with the greatest disparities in HPV vaccination and inform the development of
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targeted interventions for these populations. Also, as seen with our results in the ATL
region, large populated urban regions have high HPV and Tdap dose administration. So
comparing the utilization of HPV vaccination services among urban groupings like
metropolitan geographic areas, inner cities of large metropolitan areas, fringes of large
cities also known as suburbs, and small metropolitan areas could help examine the
sensitivity of spatial modeling strategies in estimating within county HPV vaccine dose
administration and explore additional indicators of HD clinic access.
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5.6 Figures
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5.7 Tables
Table 1. HPV & Tdap Vaccination Coverage Trends
Georgia
159

Counties (n)
HPV vaccination coverage trend:
≥1 dose, all adolescents aged 13-17
(United States overall)
2016 (60.4%)
2017 (65.5%)
2018 (68.1%)
2019 (71.5%)

67.3%
64.3%
68.1%
65.9%

2016 (88.0%)
2017 (88.7%)
2018 (88.9%)
2019 (90.2%)

92.8%
93.3%
94.2%
92.5%

Tdap vaccination coverage trend:
≥1 dose, all adolescents aged 13-17
(United States overall)

Data Sources: TeenVaxView | 2008-Present Adolescent HPV
Vaccination Coverage Trend Report | CDC and Elam-Evans LD,
Yankey D, Singleton JA, et al. National, Regional, State, and
Selected Local Area Vaccination Coverage Among Adolescents
Aged 13–17 Years — United States, 2019. MMWR Morb Mortal
Wkly Rep. 2020

Table 2. Association of administered HPV vaccine doses and indicators of
HD clinic access
Random intercept
model
Intercept
Private HD clinics
Public HD clinics
Public transit access

estimate

Exp(estimate)

P- value

5.915
0.088
0.153
0.486

370.77
1.08
1.17
1.63

< 2e-16
< 2e-16
3.51 e-08
< 2e-16
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Table 3. Posterior results for the parameter estimates of the Leroux model:
administered doses of HPV vaccine ~ Private HD clinics + Public HD clinics +
public transit
HPV vaccine parameters
Intercept
Private HD clinics
Public HD clinics
Public transit access

median
6.270
0.066
-0.056
0.423

2.5%
5.63
-0.11
-1.00
0.12

97.5%
8.91
0.15
0.20
0.80

Table 4. Association of administered Tdap vaccine doses and indicators of HD
clinic access
Fixed effects model
estimate Exp(estimate)
P- value
(AIC = 2630.12)
Intercept
6.46
638.35
< 2e-16
Private HD clinics
0.14
1.15
< 2e-16
Random intercept
model
(AIC = 2645.3)
Intercept
Private HD clinics
Public transit access

estimate

Exp(estimate)

P- value

5.97
0.08
0.32

393.52
1.09
1.38

< 2e-16
< 2e-16
7.39e-09

Table 5. Posterior results for the parameter estimates of the Leroux model:
administered doses of Tdap vaccine ~ Private HD clinics + public transit
Tdap vaccine parameters

median

2.5%

97.5%

Intercept

6.036

5.34

6.50

Private HD clinics

0.087

0.033

0.16

Public transit access

00270

-0.27

0.71
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6.1 Abstract
Objective: To predict the association between HPV vaccination coverage and health
department clinic access in GA at the county level among Tdap vaccinated adolescents.
Methods: Using a cross sectional study design, secondary data were analyzed from 2019
American Community Survey 5 year estimates, the Georgia Department of Public Health,
Georgia Registry of Immunization Transactions and Services (GRITS), and the Georgia
Department of Transportation for the years 2016 to 2018 for all 159 counties of Georgia.
The study population was male and female adolescents aged 13-17 who received their
Tdap and HPV vaccines in Georgia. Prediction models were developed using 2016-2017
data and predictions were validated using 2018 data. The number of administered HPV
vaccine doses and the HPV vaccination coverage rates were modeled using indicators of
heath department clinic access and age, sex, race/ethnicity, socioeconomic status,
education, median household income, health insurance and resident type.
Results: The prediction model for counts of administered HPV vaccine doses showed
statistical significance and a positive association with indicators of HD clinic access:
public transit and the number of HD private clinics. The prediction model for HPV
vaccination coverage rate accounted for Tdap vaccinated adolescents and was a better fit.
The prediction model for HPV vaccination coverage rate showed statistical significance
and a negative association with the variables of White race and rural residency.
Conclusion: Using data from adolescents who have received the Tdap vaccine as a
sample population established access to vaccines and controls for multiple confounders
such as vaccination ineligibility, vaccine exemption, and adolescents with parents
opposed to vaccination. Therefore, within this population, rural counties and the White
72

racial category were identified as significant predictors of a decrease in HPV vaccine
dose administration. Epidemiologists, program planners and health educators could use
these data to target HPV vaccination efforts among non-Hispanic whites and in rural
communities. Future work is needed with the use of geographically weighted regression
models to improve predictions of HPV vaccination by accounting for spatial dependence
in addition to overdispersion because this could incorporate the variability for other
unmeasured factors.
Keywords: HPV vaccine, Tdap vaccine, prediction models, small area estimation
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6.2 Introduction
The equity of access to health care services such as health screening services,
public health nursing, the number of clinics, health education, immunization services and
school health services at the county level significantly impacts Human Papillomavirus
(HPV) vaccination coverage rates. A key indicator of overall community health is
immunization coverage rates and vaccination coverage is the traditional metric used to
assess vaccine usage; however, provider orders and doses administered represent two
immediately available proxy measures1. State immunization resources and immunization
service delivery through the Health Department (HD) are organized at the county level or
local level2. Three indicators of access related to local Health Department clinics of
particular interest are the number of public and private health clinics, Vaccine For
Children (VFC) provider registration and the availability of public transportation. Public
transportation is health equity metric related to community determinants of health. Some
urban and rural communities are disproportionately affected by the access to a vehicle
which then impacts their access to health care services3.
Another metric of access is the affordability of services. Under the Vaccine for
Children (VFC) program, the Center for Disease Control (CDC) purchases vaccines at a
discount and distributes them to grantees, such as state HDs and certain local and
territorial public health agencies. These grantees distribute the vaccines at no charge to
private physicians' offices and public health clinics that are registered as VFC providers.
Because the federal government pays for the vaccine, providers are not paid for the cost
of the vaccine product. Instead, they are paid an administration fee for the costs that the
provider incurs in administering the vaccine. For children enrolled in Medicaid, the
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Medicaid program pays the vaccine administration fee. For uninsured and underinsured
children enrolled in VFC, the parents may be billed for the administration fee and the
administration fee varies by state4. While this fee is rarely pursued in the event of nonpayment, this practice could introduce a perceived barrier to vaccine access.
Georgia’s (GA) state HD immunization registry has a surveillance system that is
able to monitor at the county level how many of their clinics are public, private,
registered with the Vaccine For Children (VFC) program and the administered doses of
the HPV vaccine per clinic. Additionally, GA’s vaccination coverage trend of adolescents
receiving at least one dose of the HPV vaccine has stayed close to the national average
since 20165. However, persistent differences in HPV vaccination uptake have been
observed among adolescents who receive the Tetanus, diphtheria, pertussis (Tdap)
vaccine5,6. Even though the Tdap vaccine is school mandated, states with HPV vaccine
mandates have similar rates of HPV vaccination as those without mandates, thus
indicating that the underlining difference for vaccination uptake are not fully understood
7,8

.
With equity of access to health services, there should be no differences in

vaccination coverage by race, ethnic origin, income, geographical location or insurance
status9, yet HPV vaccine coverage rates vary by geographic location and other factors
despite similar programing and activities provided by HDs10. Prior studies have identified
factors at the local level associated with HPV vaccination coverage as the uptake of other
adolescent vaccines, gender, race/ethnicity, socioeconomic status, religiosity, political
ideology, education policies and insurance status7,11,12. However, the systematic underuse
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of immunization services by populations that share characteristics, such as education or
attitudes, indicates a problem with equity of access9.
Since data have shown Tdap vaccination rates to surpass HPV vaccination rates,
these adolescents are a prime target group for increasing HPV vaccinations. Therefore,
the objective of this study was to predict the association between HPV vaccination dose
coverage and HD clinic access in GA at the county level among Tdap vaccinated
adolescents. The rational for this study was that using adolescents who have received the
Tdap vaccine as a sample population establishes access to vaccines and controls for
multiple confounders such as vaccination ineligibility, vaccine exemption, adolescents
with parents opposed to vaccination and no access to vaccination services. Also, prior
studies that have examined factors associated with low HPV vaccination did not include
HD level variables. Therefore, this study contributes to the literature by incorporating
new variables of HD clinic access as potential explanatory factors that significantly
impact HPV vaccination dose administration at the county level. The hypothesis is that
significant factors associated with HPV vaccine dose administration will be predicted
among Tdap vaccinated adolescents at the county level in GA.
6.3 Methods
Data
Using a cross sectional study design, secondary data were analyzed from the 2019
American Community Survey 5 year estimates, the Georgia Department of Public Health,
Georgia Registry of Immunization Transactions and Services (GRITS), and the Georgia
Department of Transportation for the years 2016 to 2018 for all 159 counties of
Georgia. Data from years 2016 – 2017 were used to develop the predictive models and
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data from year 2018 were used to validate the predictive models. The study population
was male and female adolescents aged 13-17 who received their Tdap and HPV vaccines
in Georgia. The number of administered Tdap vaccine doses was used as a proxy
measure for population who received the Tdap vaccine because adolescent Tdap is a
single dose vaccine with a booster every ten years recommended for those who get it in
the 13-18 age group. Predictor variables included indicators of access to HD clinics
defined as the counts of public and private clinic sites, counts of clinic sites with Vaccine
For Children (VFC) provider registration, and the availability of public transit routes.
These variables were collected by zip code and aggregated to the county level using Zip
Code Tabulation Areas (ZCTAs) for years 2016 - 2017 and then for 2018. Table 1 shows
additional predictor variables selected as factors associated with HPV vaccination based
on previous literature review were age (percent under 18 years) , sex (percent of total
population), race/ethnicity (percent of population), socioeconomic status (percent below
poverty level under 18), education (high school graduate or higher percentage), median
household income, health insurance (percent uninsured and insured under age of 19
years) and resident type (urban and rural percentage). The education variable includes
high school graduate equivalency, some college – no degree, associate’s degree,
bachelor’s degree and graduate or professional degree.
Statistical Modeling & Analyses
Two predictive models were developed: one with a count outcome of the number
of administered HPV vaccine doses and the other, a rate outcome of HPV vaccination
dose coverage. The HPV vaccination dose coverage rate was calculated as the number of
HPV vaccination doses administered among the number of adolescents who have
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received the Tdap vaccine. The number of adolescents who received the Tdap vaccine in
years 2016 and 2017 was modeled as an offset variable, (i.e. constant term) on the log
scale to convert the number of administered HPV and Tdap vaccine doses to populationadjusted rates. The relationship between exposure variables and both outcomes were
assessed using univariate analysis. While exploring the data with Poisson regression,
overdispersion was detected so negative binomial regression was used to model13 both
outcomes. Distributional assumptions were tested and asserted. Final prediction models
were selected based on the statistical significance of informative predictors using alpha
0.05 and the Akaike Information Criterion (AIC) statistic.
The beta coefficients of the final developed models were then applied to the
external data from 2018. To evaluate prediction model performance the Root Mean
Square Error (RMSE) and coverage probabilities with 95% prediction intervals for model
calibration (i.e. agreement between observed outcomes and predictions)14,15 were
calculated. The comparative size of RMSE indicates model fit of how close the observed
data points are to the model’s predicted values. Hence a smaller RMSE value indicates
that the prediction model is better at predicting the observed data. Coverage probabilities
with a 95% prediction interval for administered doses of the HPV vaccine should include
the true value of administered dose of the HPV vaccine approximately 95% of the time.
Univariate and bivariate analyses were done in SAS statistical software version 9.4 16.
Regression analyses and predictions were implemented in R V.3.6.3 software packages17.
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6.4 Results
Dose Count Outcome Prediction Model
The prediction model for the number of HPV vaccine administered doses was
initially fit maintaining all of the predictor variables. Several of the predictor variables
were statistically significantly associated with the number of HPV vaccine administered
doses: rural residency, education, poverty, age, Asian, Hispanic, public transit and HD
private clinics (Table 2). These estimates are interpreted individually holding all the other
variables constant: 1) a one percent increase in rural residency decreases the number of
HPV vaccine administered doses by 0.03%. 2) A change from no to yes in access to
public transit increases the number of HPV vaccine administered doses by 1.32%. 3) An
increase of one HD Private clinic increases administered doses of the HPV vaccine by
1.04%. The remaining estimates can be interpreted similarly. After applying the final
developed count model to 2018 data, the coverage probability of model calibration was
86.8% and can be interpreted as the probability that the prediction interval contains the
true values of HPV vaccine administered doses approximately 87% of the time.
Dose Coverage Rate Outcome Prediction Model
The HPV vaccination dose coverage rate prediction model was initially fit
maintaining all of the predictor variables. Two of the predictor variables were statistically
significantly associated with the number of administered doses of HPV vaccine among
adolescents who received the Tdap vaccine: rural resident type and the White racial
category (Table 3). These estimates are interpreted individually holding all the other
variables constant: 1) a one percent increase in rural residency decreases the HPV
vaccine dose coverage rate by 0.72%. 2) A one percent increase in White racial category
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decreases the HPV vaccine dose coverage rate by 0.51%. After applying the final
developed rate model to 2018 data, the coverage probability of model calibration was
98.1% and can be interpreted as the probability that the prediction interval contains the
true values of HPV vaccine dose coverage rates approximately 98% of the time.
6.5 Discussion
Interpretation
In this study two prediction models were developed from 2016 and 2017
data, one using counts of administered HPV vaccine and the other using an HPV
vaccination dose coverage rate. Both were validated using counts of administered HPV
vaccine doses from year 2018. Both models used demographic data and indicators of HD
clinic access as predictors at the county level. Both models at the county level predicted
statistically significant factors of HPV vaccine dose administration. However, only the
prediction model for counts of administer HPV vaccine doses showed statistical
significance with indicators of HD clinic access: public transit and the number of HD
private clinics. The prediction model for HPV vaccination dose coverage rates included
Tdap vaccinated adolescents and was a better fit for the data because of lower AIC and
RMSE values. Therefore, among adolescents who have received the Tdap vaccine, the
dose coverage rate prediction model identified two prognostic factors of rural residency
and the racial category of White as statistically significantly associated in a negative
direction with administered doses of the HPV vaccine at the county level. Further
examination of these demographic variables may explain the additional differences
between HPV and Tdap vaccine uptake because in the prediction model for counts of
administered HPV doses, the negative effect of rural residency was less (0.03% compared
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to a 0.72% effect in the dose coverage rate prediction model) and the White racial
category did not show statistical significance.
In relation to public health efforts, the National Immunization Survey-Teen (NISTeen) only provides state and national level rates with some large regional variation that
can be examined. This study used prediction modeling and public health data sources, to
estimate county level HPV vaccination rates. This novel approach enables people
working at the community level to use these data to inform HPV vaccination promotion
outreach efforts because this study showed that adolescents receiving the Tdap vaccine,
the White racial category and rural residency affect the administration of HPV vaccine
doses. These results are similar to previous studies that found decreased HPV vaccine
initiation in rural communities18,19 and among non-Hispanic white adolesents20 and that
the coadministration of the Tdap vaccine is helpful for HPV vaccine uptake21. These
results were different from previous studies that found significant associations of county
level estimates with Hispanic ethnicity, county poverty, household and percentage of
uninsured22,23. However, these differences may be due to the limitation of the study
population to girls.
Limitations
There are several limitations to acknowledge in this study. Counts of administered
vaccine doses are only from clinic sites that report to the state’s immunization registry.
As such, there may be administered vaccination doses that are not accounted for and
result in the underestimation of administered HPV and Tdap vaccine doses. Second,
adolescents should have just received one dose of the Tdap vaccine within the study
period, but it is possible that duplication vaccination may have occurred for a small
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number of patients. Third, these prediction estimates are not geographically weighted to
account for spatial variability. This absence may be evidenced by the rate prediction
model’s coverage probability of 98%, which is a little high and may indicate some
inaccuracy of those predictions due to the confidence interval being wider than
necessary14 but this coverage probability also highlights valid and precise predictions.
There are several strengths to this study. This study is one of the first to predict HPV
vaccine dose coverage rates among adolescents who received the Tdap vaccine at the
county level. These results found multiple statistically significant variables associated
with HPV vaccine dose administration but emphasize rural residency and the White racial
category as the variables to account for with HPV vaccination efforts. Additionally, this
methodology can be used in different states that have vaccination registries with
disaggregated population-level data to estimate small area HPV vaccination rates or these
models can be generalized to other states with similar population demographics.
Conclusion
Overall, this study showed the effect of accounting for adolescents who have
received the Tdap vaccine when investigating HPV vaccine dose administration. The
rate prediction model used in this study has important implications for HDs since state
immunizations resources and immunization service delivery are organized as the county
or local level. Using adolescents who have received the Tdap vaccine as a sample
population established access to vaccines and controlled for multiple confounders such as
vaccination ineligibility, vaccine exemption, adolescents with parents opposed to
vaccination and no access to vaccination services. Therefore, within this population,
increases in rural communities and the White racial population percentages were
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identified as significant predictors of a decrease in HPV vaccine dose administration.
Epidemiologists within HDs, program planners and health educators could use these data
to focus HPV vaccination intervention efforts among non-Hispanic whites and in rural
communities. To further improve HPV vaccination interventions, future work is needed
with the use of geographically weighted regression models to improve predictions of
HPV vaccination dose administration by accounting for spatial dependence in addition to
overdispersion because this could incorporate the variability for other unmeasured
factors. Additional small area studies on additional vaccines recommended by the
Advisory Committee on Immunization Practices (ACIP) such as Meningococcal
conjugate, Measles, mumps and Rubella (MMR) and hepatitis B (HepB) would help to
evaluate the application of predictive and other modeling strategies estimating county
level vaccine coverage for delivering HD immunization resources.
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6.6 Tables
Table 1. Overall Population Demographic Characteristics
Georgia
Counties
159
HPV vaccination coverage trend:
≥ 1 dose, all adolescents aged 13-17*
(United States overall)*
2016 (60.4 %) 67.3%
2017 (65.5 %) 64.3%
2018 (68.1 %) 68.1%
Tdap vaccination coverage trend:
≥ 1 dose, all adolescents aged 13-17*
(United States overall)
2016 (88.0 %) 92.8%
2017 (88.7 %) 93.3%
2018 (88.9 %) 94.2%
§
Race Ethnicity
Black/African American 31.6%
White 58.6%
Asian 4.0%
Hispanic 9.5%
American Indian/Alaskan Native 0.4%
Native Hawaiian/Other Pacific Islander 0.1%
Below 18 years of age§
24.1%
§
Education attainment
Highschool graduate or higher 87.5%
Median Household Income§
$58,700
§
Under 19 uninsured
7.2%
Under 19 insured §
92.8%
§
Under 18 below poverty level
21.5%
¶
Living in rural area
24.9%
¶
Living in urban area
75.0%
Data Sources:
* (Walker et al., 2019)
§ (U.S. Census Bureau, 2015-2019 American Community Survey 5-Year
Estimates)
¶ (U.S. Census Bureau, 2010 Census.)
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Table 2. Results of count prediction model for administered doses of HPV vaccine
Variables
Intercept
rural
education
poverty
age
Asian
Hispanic
Public transit (yes)
HD private clinics

estimate
5.61
-3.44
2.80
-2.25
3.91
-12.30
3.20
0.28
0.04

Exp(estimate)
273.66
0.03
16.52
0.10
50.04
0.00
24.49
1.32
1.04

P- value
1.35 e-06
< 2 e -16
0.01
6.70 e-06
0.02
0.0006
0.001
0.02
2.60 e-11

HPV = human papillomavirus; HD = health department

Table 3. Results of coverage rate prediction model for administered doses of HPV
vaccine among adolescents who received the Tdap vaccine
Variables

estimate

Exp(estimate)

P- value

Intercept
0.65
1.92
1.83 e-08
rural
-0.33
0.72
0.001
White
-0.68
0.51
5.33 e-05
HPV = human papillomavirus; Tdap = Tetanus, diphtheria and pertussis; HD = health
department
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7.1 Abstract
Objective: To use GA as a predictor model to provide greater insight of where to more
efficiently allocate HPV vaccination resources at the county level within SC and inform
the implementation and dissemination of HPV vaccination interventions that focus on the
use and quality of state immunization resources.
Methods: Using a cross sectional study design, secondary data were collected from 2015
– 2019 estimates of the American Community Survey, the Georgia Department of Public
Health, Georgia Registry of Immunization Transactions and Services (GRITS), and the
Statewide Immunization Online Network of South Carolina Department of Health and
Environmental Control (SC DHEC) for the years 2016 to 2018 for all counties of GA and
SC. The study population was all male and female adolescents aged 12-18 in SC based on
the age groups reported by DHEC’s SIMON and available census data. The number of
adolescents who received one dose of the Tdap vaccine was used as an offset variable to
calculate HPV vaccination coverage rates. Using the beta estimates of white and rural
from the final GA prediction model, three predictive models for SC were developed using
negative binomial regression to compare three different time spans for the best model fit.
Results: The best fitting prediction model for SC was for the 2018 one-year time span
even though the prediction model based on GA was developed using 2016-2017 data.
This suggests that the HPV vaccination coverage prediction model is more helpful when
looking at a single subsequent year. Negative residual estimates indicated over prediction
and the counties of Charleston, Greenville and Richland had the largest differences
between their observed and predicted HPV vaccination coverage rates.
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Conclusion: These results suggests the need for implementation and dissemination of
HPV vaccination interventions that focus on the use and quality of state immunization
resources in Charleston, Greenville and Richland counties. The observed HPV
administered dose coverage in these counties is not largely indicative of white and rural
county residents and adolescents who have received the Tdap vaccine; otherwise the
predicted administered dose coverage rates would be closer to the observed. These results
highlight the need for prediction modeling studies at a local level to help with public
health decision making, low HPV vaccination coverage and limited or no immunization
registry data for small geographic areas.

Keywords: Prediction modeling, HPV vaccine, South Carolina, Georgia, immunization
registry, public health
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7.2 Introduction
National and regional efforts are being made to increase Human Papillomavirus
(HPV) vaccination to 80% 1. The between state variation of HPV vaccination may be due
to limited HPV vaccination surveillance2. Since HPV infections and most HPVassociated conditions are not a nationally notifiable2 health-care claims data from
adolescents and adults with employer-provided private health insurance in the United
States are used to examine the population effectiveness of HPV vaccinations on HPV
infections3. Furthermore, within state variability of HPV vaccination is not commonly
studied. This may be due to the lack of state immunization registry data available at the
zip code and county level4,5. These limited data on HPV prevalence in small geographic
areas contribute to a limited capacity to characterize vaccination at smaller geographic
levels such as county and zip code6. With immunization resources often delivered and
utilized at the county level7, to assess HPV vaccine usage, a proxy measure for
vaccination coverage is dose administration8.
The states of Georgia (GA) and South Carolina (SC) are both in public health
region IV and therefore share the same regional office for programs and policies through
the U.S. Department of Health and Human Services (HHS) (Figure 2). Despite the
difference in the number of counties, GA and SC share similar population demographic
characteristics9–11 (Table 1). During the years of 2016 to 2018, the estimated HPV
vaccination coverage trends of GA’s Tdap and HPV vaccination rates were consistently
near or greater than the national average. Conversely, SC was consistently below the
national average with the lowest HPV vaccination coverage estimate in the United States
in 2016 according to the National Immunization Survey – Teen data12. Systematic
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underuse of services that impact health by populations that share similar demographic
characteristics may indicate a problem with equity of access13. Hence, access may be a
significant driver of the different HPV vaccination rates between GA and SC. GA has
comprehensive adolescent HPV vaccination data available through the Georgia
Immunization Registry (GRITS) of the Georgia Department of Public Health at the zip
code level that can be aggregated to the county level using Zip Code Tabulation Areas.
SC does not have zip code level, but rather counts of administered HPV vaccine doses at
the county level available through their Statewide Immunization Online Network. In
order to explore these differences at the county level in SC, the availability of zip code
level HPV vaccination data in GA, coupled with its similar population demographics to
SC, supports GA as a suitable model state for developing a working plan to increase SC’s
county level HPV vaccination coverage rates.
Therefore, the objective of this research was to use GA as a predictor model to
provide greater insight of where to more efficiently allocate HPV vaccination resources at
the county level within SC and inform the implementation and dissemination of HPV
vaccination interventions that focus on the use and quality of state immunization
resources. The hypothesis is that differences in SC’s vaccination coverage between
observed and predicted rates will be identified.
7.3 Methods
Data
Using a cross sectional study design, secondary data were collected from 2015 –
2019 estimates of the American Community Survey, the Georgia Department of Public
Health, Georgia Registry of Immunization Transactions and Services (GRITS), and the
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Statewide Immunization Online Network of South Carolina Department of Health and
Environmental Control (SC DHEC) for the years 2016 to 2018 for all counties of GA and
SC. The study population was all male and female adolescents aged 12-18 in SC based on
the age groups reported by DHEC’s SIMON and available census data. For the predicted
HPV vaccination coverage rate, adolescents who have received one dose of the Tdap
vaccine were the sample population to establish access to vaccines and control for
multiple confounders such as vaccination ineligibility, vaccine exemption, adolescents
with parents opposed to vaccination and no access to vaccination services. To calculate
the observed HPV vaccination coverage rate, the counts of administered HPV vaccine
doses were reported by SC DHEC for ages 13-18 and the total number of adolescents in
South Carolina were from ages 12-17 because it was the closest prespecified age group
available in the US Census data for years 2016, 2017 and 2018.
Statistical Modeling & Analyses
The GA prediction model applied to SC data was developed using 1) adolescents
aged 13-17. 2) Variables related to indicators of health care access via health care
utilization13: the number of public health department clinics, the number of health
department private clinics and the number of HD clinics with VFC provider registration.
3) A variable related to health equity14: public transit transportation. 4) Predictor
variables from factors associated with HPV vaccination based on a literature review6,15,16:
age (percent under 18 years) , sex (percent of total population), race/ethnicity (percent of
population), socioeconomic status (percent below poverty level under 18), education
(high school graduate or higher percentage), median household income, health insurance
(percent uninsured and insured under age of 19 years) and resident type (urban and rural
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percentage). All variables were aggregated to county level using Zip Code Tabulation
Areas (ZCTAs). The final GA prediction model with the best performance only included
the predictor variables of white and rural.
Using the beta estimates from the final GA prediction model, three predictive
models for SC were developed using negative binomial regression. All the models also
included the number of adolescents who received the Tdap vaccine as an offset (i.e.,
constant term) on the log scale to convert the HPV vaccine administered dose counts to
HPV vaccination coverage rates. Model 1 predicted HPV vaccination coverage for years
2016 and 2017 combined to estimate the same year time span of the data used to develop
the GA prediction model. Model 2 predicted HPV vaccination coverage for year 2018 to
estimate the year following the time span of the data used to develop the GA prediction
model, and model 3 predicted HPV vaccination coverage for years 2016, 2017 and 2018
combined to estimate the years included and after the time span of the data used to
develop the GA prediction model. To evaluate prediction model performance, residuals
were assessed and the Root Mean Square Error (RMSE) was calculated. The residual is
the difference between observed and predicted administered HPV vaccine rates. The
closer the residuals are to zero, the better the model fits the data. Residual outliers were
calculated using the Interquartile Range (IQR). The comparative size of RMSE indicates
model fit of how close the observed data points are to the model’s predicted values.
Hence a smaller RMSE value indicates the better prediction model. Regression analyses
and model predictions were implemented in R V.3.6.3 software packages17. Choropleth
maps18 of observed and predicted administered HPV vaccine rates were created with SAS
statistical software version 9.4 19.
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7.4 Results
Data Maps
Choropleth maps show the observed administered HPV vaccine coverage
compared to the predicted administered HPV vaccine coverage among Tdap vaccinated
adolescents. For all three time periods, the clustering patterns of observed and predicted
rates of HPV vaccine coverage across counties are somewhat similar. However, there is a
clear pattern of increased predicted rates is some counties (Figure 1).
HPV vaccine dose coverage 2016-2017
The negative residual estimates of the prediction model for HPV vaccination dose
coverage 2016 – 2017 can be interpreted as the average coverage rate of administered
HPV vaccine was over predicted by 721 doses based on the mean, 25% of coverage rates
were over predicted by 896 doses based on the first quartile and 75% of coverage rates
were over predicted by 191 doses based on the third quartile (Table 2). Figure 2 shows
the values of the residuals for each county for 2016 - 2017. Negative residual values
indicate over prediction. The lighter shades indicate a range of larger differences between
observed and predicted HPV vaccination coverage and the darker shades indicate a
smaller range of differences. Of the lighter shaded counties (i.e. counties with larger
differences), Figure 3 shows that the residuals of three counties were calculated to be
outliers (i.e. abnormally different): 10 – Charleston, 23- Greenville and 40 – Richland.
Therefore, these counties need further examination to understand why the predicted HPV
vaccination coverage was much higher than the observed compared to the other counties
for 2016-2017. The RMSE for this model was 2384.3.
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HPV vaccine dose coverage 2018
The negative residual estimates of the prediction model for HPV vaccination dose
coverage 2018 can be interpreted as the average coverage rate of administered HPV
vaccine was over predicted by 339 doses based on the mean, 25% of coverage rates were
over predicted by 447 doses based on the first quartile and 75% of coverage rates were
over predicted by 77 doses based on the third quartile (Table 2). Figure 2 shows the
values of the residuals for each county for 2018. Of the lighter shaded counties (i.e.
counties with larger differences), Figure 3 shows that the residuals of three counties were
calculated to be outliers: 10 – Charleston, 23- Greenville and 40 – Richland. Therefore,
these counties need further examination to understand why the predicted HPV
vaccination coverage was much higher than the observed compared to the other counties
for 2018. The RMSE for this model was 553.8.
HPV vaccine dose coverage 2016-2018
The negative residual estimates of the prediction model for HPV vaccination dose
coverage 2016 - 2018 can be interpreted as the average coverage rate of administered
HPV vaccine was over predicted by 1,060 doses based on the mean, 25% of coverage
rates were over predicted by 1,362 doses based on the first quartile and 75% of coverage
rates were over predicted by 282 doses based on the third quartile (Table 2). Figure 2
shows the values of the residuals for each county from 2016 - 2018. Of the lighter shaded
counties, Figure 3 shows that the residuals of three counties were calculated to be
outliers: 10 – Charleston, 23- Greenville and 40 – Richland. As outliers, these counties
need further examination to understand why the predicted HPV vaccination coverage was
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much higher than the observed compared to the other counties for 2016 - 2018. The
RMSE for this model was 1735.3.
7.5 Discussion
Interpretation
In this study vaccination coverage rates of administered HPV vaccine doses
among Tdap vaccinated adolescents in South Carolina were predicted using a model
developed from GA. GA’s availability of zip code level HPV vaccination data coupled
with its similar population demographics to SC, supports GA as a novel and suitable
model state for developing a working plan to increase SC’s county level HPV vaccination
coverage rates. These prediction models are also unique because the Tdap vaccine is a
one-shot series and the HPV vaccine is a two-shot series before the age of 15 and a threeshot series after the age of 15. These predictions highlight what HPV vaccination
coverage rates could be if each adolescent that received a Tdap vaccine received at least
one dose of the HPV vaccine. Therefore, these predictions are best compared to HPV
vaccination initiation instead of series completion.
Three prediction models were designed to evaluate which time span best fit the
data. The negative residuals values of the counties indicate over prediction. The
differences of HPV vaccine coverage rates were illustrated with multiple choropleth
maps and supported with quantitative analyses. Under the prediction model assumptions,
results clearly show that the predicted HPV vaccine coverage rates among Tdap
vaccinated adolescents were higher than observed rates among all SC adolescents. This
over prediction is interesting because the prediction model accounts for the variables of
white race and rural residency. Therefore, these results suggest that among South
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Carolinians within the white racial category and rural counties, if the adolescents who
received the Tdap vaccine also received the HPV vaccine, the number of HPV vaccine
administered doses would be greater. Accordingly, this frame of reference is useful to
public health professionals and clinicians because it supports the co-administration of the
HPV vaccine with the Tdap vaccine.
The best fitting prediction model for SC was for year 2018. This is interesting
because the prediction model based on GA was developed using 2016-2017 data. This
suggests that the HPV vaccination coverage prediction model is more helpful when
looking at a subsequent year. Within this model all of the counties fell below the national
average of 68.1% for 201820. However, the counties of Charleston, Greenville and
Richland had the largest differences between their observed and predicted HPV
vaccination coverage rates. These residual differences suggests the need for further
investigation because 1) the prediction model was based on county level rural residency
and the white racial category but all three of these counties are designated as urban by the
U.S. Census Bureau, the U.S. Department of Agriculture, Economic Research Service
and the U.S. Office of Management and Budget21. Therefore, these residuals suggest that
the observed HPV administered dose coverage rates in these counties are not largely
indicative of white and rural county residents, because the predicted administered dose
coverage rates would be closer to the observed. 2) Predictions were made using a subset
of the population, adolescents who received the Tdap vaccine. Therefore, these residuals
also suggest that the observed HPV administered dose coverage rates in these counties
are not largely indicative of white and rural county residents and adolescents who have
received the Tdap vaccine. These results highlight that prediction modeling studies are
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needed at a local level because many of the HPV vaccine modeling studies designed to
help with public health decision making are at the national and state level.
This study showed that predicting and visualizing HPV vaccination coverage rates
at the county level is helpful for identifying within state variability and indicating
counties that need further examination. There are no studies to our knowledge that use
prediction modeling for HPV vaccination coverage rates or vaccine dose administration
at the county level6,22. Many other studies use predictive modeling to assess HPV
knowledge and behavior 15,23–26. However, the results of this study are similar to previous
studies that found that visualizing vaccination data at the county level can help multiple
stakeholders, such as local and state health departments, pharmacists, insurers, and
nonprofit organizations determine where to focus financial and physical resources to
improve HPV vaccination and identify gaps in vaccine delivery 27–29.
Limitations
There are several limitations to acknowledge in this study. First, currently it is not
possible to differentiate if an administered dose was given to initiate or complete an HPV
vaccination series due to immunization registry data not being linked with vital records.
With the data not being able to distinguish between the doses, it better to use HPV
initiation a comparator for the predicted HPV vaccine administered dose coverage rates
in this study since adolescents who received one dose of the Tdap vaccine were used to
create the predictions. Second, the assumption that previously collected data can predict
the future is not always accurate. Using associations from historical data to predict the
future also assumes there are certain lasting conditions, such as number of doses needed
to complete the vaccine series and age range of use. These inaccurate assumptions of
lasting conditions can lead to inaccurate estimates30. Another potential complication with
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predictive modeling is the possibility of new variables that have not been considered or
even defined are critical to the outcome such as the number of school based health
centers/clinics within a county, which could serve as an additional source of HPV vaccine
delivery especially in rural counties. Until these and other measures become available,
the use of proxy measures will need to be taken with caution. However, there are also
several strengths to this study. This study is one of the first studies to apply predictive
modeling to HPV vaccination dose administration at the county level. Furthermore, this
study innovatively used a vaccinated population for modeling estimates, which supports
the importance of co-administering the HPV vaccine with other scheduled adolescent
vaccines to improve HPV vaccination rates. Another strength is that this methodology is
applicable to other states with similar population demographics, low HPV vaccination
coverage and limited or no immunization registry data for small geographic areas.
Conclusion
Overall, this study showed that immunization registries can be informative data
sources for public health practitioners to identify priorities for HPV vaccinations
interventions in targeted locations. Based on these results, a working plan to address the
current limitations of SC’s HPV vaccination coverage at the county level is to
disaggregate statewide immunization resources and identify barriers to HPV vaccine
access and delivery in Charleston county in the Lowcounty, Greenville county in the
Upstate and Richland county in the Midlands region. Public health practitioners should
first examine the similarities of county level characteristics such as race/ethnicity
percentages, areas of rural residency and provider shortage areas because prior research
has shown them to be associated with variation in HPV vaccination6. Once these county
level area characteristics are identified, then practitioners can focus on regional
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differences to develop systems level interventions that include HPV vaccine delivery and
access to HPV vaccination services. To better inform HPV vaccine delivery, future work
is needed with the use of health indices such as the social vulnerability index to help
public health officials and practitioners plan, prepare and respond to public health needs.
Additional predictive studies using other adolescent vaccines such as the meningococcal
conjugate vaccine (MCV4) or other proxy measures for vaccination usage such as
provider orders, would help to evaluate the application of predictive modeling strategies
for better immunization resource allocation.
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7.6 Figures
Figure 1. Maps of observed and predicted HPV vaccine coverage rates
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Figure 2. Maps of residual HPV vaccination coverage
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Figure 3. Residual plots for all models
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7.7 Tables
Table 1. Population Demographic Characteristics
Georgia
Counties
159
HPV vaccination coverage trend:
≥ 1 dose, all adolescents aged 13-17*
(United States overall)*
2016 (60.4 %) 67.30%
2017 (65.5 %) 64.30%
2018 (68.1 %) 68.10%
Tdap vaccination coverage trend:
≥ 1 dose, all adolescents aged 13-17*
(United States overall)
2016 (88.0 %) 92.80%
2017 (88.7 %) 93.30%
2018 (88.9 %) 94.20%
+
Race Ethnicity
Black/African American 31.30%
White 52.80%
Asian 4.20%
Hispanic 9.60%
American Indian/Alaskan Native 0.50%
Native Hawaiian/Other Pacific Islander 0.10%
Below 18 years of age+
24.10%
Education+
Highschool graduation 81%
Some College 63%
Median Household Income+
Uninsured children+
Children in poverty+
Living in rural area+

$56,100
7%
22%
24.90%

South Carolina
46

44.20%
59.60%
63.70%

77.50%
89.40%
88.90%
26.80%
63.80%
1.70%
5.70%
0.50%
0.10%
22.00%
84%
62%
$50,700
4%
22%
33.70%

Data Sources:
* (Walker et al., 2019)
+ (“County Health Rankings & Roadmaps,” 2019)
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Table 2. Results for the estimates of South Carolina Prediction Models
Residuals
South Carolina
Mean
1st Quartile
3rd Quartile
Prediction Models
Model 1: HPV Vaccination
-721.1
-896.0
-190.9
coverage for 2016 - 2017
Model 2: HPV Vaccination
-338.6
-447.1
-76.8
coverage for 2018
Model 3: HPV Vaccination
-1059.8
-1362.4
-282.4
coverage for 2016 - 2018

RMSE
1183.6
553.8
1735.3
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8.0 DISCUSSION
HPV vaccinations are safe, effective, and long lasting1. However, they are being
underutilized in the United States. A metric to assess vaccine usage is vaccination
coverage, which can be measured using administered doses2. Factors associated with
HPV vaccination coverage have been shown to include the uptake of other adolescent
vaccines, gender, race/ethnicity, socioeconomic status, religiosity, political ideology,
education policies and insurance status. As a result, national and state efforts are being
made to increase HPV vaccination coverage to 80% by the year 20303. However, health
care utilization can also be determined by access to public health resources that are often
managed by state the Health Department (HD): such as childhood and adolescent
vaccinations administered by school nurses and at public or private health clinics,
community education and outreach, vaccine program enrollment, and immunization
registry reporting4–6. To effectively monitor public health resource utilization, data
beyond the state level is needed but this is a limitation for some states. Therefore, the
underutilization of the HPV vaccine may be due to limited surveillance. Thus, the main
goal of this research was to generate a predictive model of county level HPV vaccination
coverage rates in GA and SC to address access barriers to HPV vaccine uptake. The main
hypothesis was that HPV vaccine coverage rates are associated with the equity of access
to HD clinics.
Using a secondary data analysis of vaccination data from both states, this research
was conducted in three specific Aims. The first Aim characterized all counties in GA by
quantifying administered doses of the HPV and Tdap vaccines collected by the state
health department immunization registries and indicators of HD clinic access. Indicators
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of HD clinic access consisted of number of private and public HD clinics, number of HD
clinics registered in the VFC program and the availability of public transportation. This
Aim incorporated choropleth maps, regression modeling and Bayesian spatial analysis.
The results of Aim 1 showed that administered doses of the Tdap vaccine and the HPV
vaccine exhibited spatial patterns shown with maps and a spatial relationship across
counties. Accounting for this spatial dependence, the number of private health
department clinics had a significant positive effect on the administered Tdap vaccine
doses and the availability of public transportation had a significant positive effect on
administered HPV vaccine doses.
Building from the first Aim, the second Aim predicted the association between
HPV vaccination coverage and HD clinic access in GA at the county level among Tdap
vaccinated adolescents. This Aim incorporated known factors associated with HPV
vaccination coverage in addition to hypothesized indicators of HD clinic access, and
adolescents who received the Tdap vaccine as a sample population to establish access to
vaccines and control for multiple confounders. The results of Aim 2 showed that the best
prediction model for HPV vaccination coverage was not associated with indicators HD
clinic access but had a statistically significant negative association with the White racial
category and rural residency. Therefore, within this population, the White racial category
and rural counties were identified as predictors of decreasing HPV vaccine dose
administration.
Extending from the second Aim, the third Aim used GA as a predictor model to
provide greater insight of where to more efficiently allocate HPV vaccination resources at
the county level within SC and inform the implementation and dissemination of HPV
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vaccination interventions that focus on the use and quality of state immunization
resources. This Aim incorporated the betas from the best prediction model using GA’s
comprehensive HPV vaccination data and applied them to SC county data over three
different time spans. The results of Aim 3 showed that the best fitting prediction model
for SC was for the 2018 one-year time span. Negative residual estimates indicated over
prediction and the counties of Charleston, Greenville and Richland had the largest
differences between their observed and predicted HPV vaccination dose coverage.
Therefore, the residuals of these three counties suggest the need for further investigation
of what HPV vaccination resources are available, being used and needed.
Based on all three Aims, HPV vaccination coverage rates are not associated with
this study’s unique variables of HD clinic access as hypothesized. However, the
indicators of HD clinic access did show statistical significance with counts of HPV
vaccine administered doses; as well spatial dependence with the counts of HPV vaccine
administered doses. This research showed HPV vaccination variability at the county level
and presented reproducible methodologies that can be used by public health researchers
and practitioners in states with low HPV vaccination coverage and limited or no
immunization registry data for small geographic areas.
While research on HPV vaccination has been conducted for over 10 years,
incorporating geographic factors and analyses is not commonly used7–9. Therefore, this
research contributed to the current literature and showed the importance of considering
spatial variation at the county level when examining HPV vaccine dose administration.
Other state based studies also found that HPV vaccination rates vary geographically10,
HPV vaccination has a strong spatial dependence when identifying and estimating factors
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associated with HPV vaccine uptake11 and that spatial accessibility to vaccination
providers increases overall vaccination12. Using aggregated zip code level data, this
research showed that adolescents receiving the Tdap vaccine, the White racial category
and rural residency affect the administration of HPV vaccine doses. Other zip code based
studies found decreased HPV vaccine initiation in rural communities13,14 and among nonHispanic white adolesents15 and that the coadministration of the Tdap vaccine is helpful
for increasing HPV vaccine uptake16. Using predictive modeling, this research showed
that predicting state immunization data at the county level was helpful for identifying
within state variability and indicating counties that need further examination. This
methodology was uniquely applied to HPV vaccination coverage because other
prediction modeling studies assess HPV knowledge and behavior 17–21.
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9.0 CONCLUSION
Local immunization coverage rates vary widely and the extent to which public
health services are delivered depends on the level of surveillance performed by the
Health Department. This research uniquely utilized the tools of mapping and prediction
modeling to extend HPV vaccination coverage rates to the county level. Mapping spatial
patterns provided a visual context to HPV vaccination data that is helpful for informing
the development of public health interventions and guiding the provision of health
services financially and physically. The underuse of the HPV vaccine is a serious but
correctable threat to progress against cancer. Using the models or methodology from this
research could inform specific recommendations for new strategies and the adaptation of
current efforts to increase HPV vaccination coverage in SC and other states with low
HPV vaccination rates. Furthermore, this research could then be used to predict
correlations to the incidence of HPV-associated cancers. This would aid the field of
health services research to understand and address health care inequities among
populations with high rates of HPV cancers, which may help reduce public health costs,
morbidity, and mortality.
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10. FUTURE DIRECTIONS
To enhance the use of predictive modeling with HPV vaccination at the county
level, new variables need to be considered and defined because they could be critical for
improving estimations and reducing confounding. For example, the number of schoolbased health centers/clinics within a county could serve as an additional source of HPV
vaccine delivery especially in rural counties. The reproducibility of prediction models
also allows them to be used by various levels of public health practitioners to inform and
guide their planning, dissemination and implementation of interventions. Additionally,
health services research would benefit from the disaggregation of statewide resources and
data from immunization registries at the county level or smaller. With more small area
data, subtle barriers to HPV vaccine uptake not seen at the state or national level could be
identified. Furthermore, with the availability of more small area data, the importance of
using maps to visualize the data highlights the need for the collaboration of multiple
stakeholders, such as local and state health departments, pharmacists, insurers,
universities, epidemiologists, statisticians and nonprofit organizations.
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